[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1977
1. Hernàndez DE, Hernàndez AE: Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor. Eur J Cancer Care (Engl); 2006 Dec;15(5):493-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
  • The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin's lymphoma (NHL) patients is very expensive in developing countries.
  • We treated 22 HIV-associated diffuse NHL patients with standard-dose CHOP and used G-CSF after an episode of febrile neutropenia until neutrophil count reached 1000/mm3.
  • There were no toxicity-related deaths.
  • Our experience showed that we can treat HIV-related NHL patients with full-dose CHOP, achieve good responses and have an acceptable toxicity profile, with the use of G-CSF as needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177909.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


2. Hendrickson SL, Lautenberger JA, Chinn LW, Malasky M, Sezgin E, Kingsley LA, Goedert JJ, Kirk GD, Gomperts ED, Buchbinder SP, Troyer JL, O'Brien SJ: Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression. PLoS One; 2010 Sep 21;5(9):e12862
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression.
  • Mitochondrial pathogenesis occurs in HIV patients and genetically, mitochondrial DNA haplogroups with presumed functional differences have been associated with differential AIDS progression.
  • METHODOLOGY/PRINCIPAL FINDINGS: Here we explore whether single nucleotide polymorphisms (SNPs) within 904 of the estimated 1,500 genes that specify nuclear-encoded mitochondrial proteins (NEMPs) influence AIDS progression among HIV-1 infected patients.
  • We examined NEMPs for association with the rate of AIDS progression using genotypes generated by an Affymetrix 6.0 genotyping array of 1,455 European American patients from five US AIDS cohorts.
  • With a Bonferroni adjustment for the number of genes and tests examined, multiple SNPs within two NEMP genes showed significant association with AIDS progression: acyl-CoA synthetase medium-chain family member 4 (ACSM4) on chromosome 12 and peroxisomal D3,D2-enoyl-CoA isomerase (PECI) on chromosome 6.
  • CONCLUSIONS: Our previous studies on mitochondrial DNA showed that European haplogroups with presumed functional differences were associated with AIDS progression and HAART mediated adverse events.
  • The modest influences of nuclear-encoded mitochondrial genes found in the current study add support to the idea that mitochondrial function plays a role in AIDS pathogenesis.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Host Microbe. 2008 Nov 13;4(5):495-504 [18976975.001]
  • [Cites] J Infect Dis. 2011 May 15;203(10):1491-502 [21502085.001]
  • [Cites] Retrovirology. 2009;6:5 [19146679.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):111-6 [19339895.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jul 1;16(10):995-1005 [10890361.001]
  • [Cites] Genome Res. 2001 Jul;11(7):1198-204 [11435401.001]
  • [Cites] Free Radic Biol Med. 2002 Mar 1;32(5):414-20 [11864781.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19579-84 [11916962.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):1102-9 [12097419.001]
  • [Cites] Free Radic Biol Med. 2002 Jul 15;33(2):192-200 [12106815.001]
  • [Cites] J Virol. 2003 Jan;77(2):1392-402 [12502855.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1908-13 [12552096.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] J Med Virol. 2003 Aug;70(4):497-505 [12794710.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Dec 25;36 Suppl 7:1S-20S [2826984.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]
  • [Cites] NIDA Res Monogr. 1991;109:75-100 [1661376.001]
  • [Cites] J Acquir Immune Defic Syndr. 1992;5(5):490-6 [1560346.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 May;15(2):208-18 [8498644.001]
  • [Cites] FEBS Lett. 1993 Sep 27;331(1-2):182-6 [8104823.001]
  • [Cites] AIDS. 1994 Aug;8(8):1123-8 [7986410.001]
  • [Cites] Biochim Biophys Acta. 1999 May 31;1454(1):126-31 [10354522.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21797-803 [10419495.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):456-64 [10508479.001]
  • [Cites] Virus Res. 2005 Oct;113(1):26-35 [15885842.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Annu Rev Genet. 2005;39:359-407 [16285865.001]
  • [Cites] Am J Clin Nutr. 2006 May;83(5):1193-8 [16685065.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):904-9 [16862161.001]
  • [Cites] PLoS Pathog. 2006 Aug;2(8):e79 [16933987.001]
  • [Cites] J Virol. 2007 Jul;81(14):7571-83 [17494070.001]
  • [Cites] J Lipid Res. 2007 Dec;48(12):2736-50 [17762044.001]
  • [Cites] PLoS Genet. 2008 Jan;4(1):e4 [18208329.001]
  • [Cites] Science. 2008 Feb 15;319(5865):921-6 [18187620.001]
  • [Cites] J Virol. 2008 May;82(9):4320-30 [18287243.001]
  • [Cites] Cell. 2008 Jul 11;134(1):112-23 [18614015.001]
  • [Cites] Apoptosis. 2008 Sep;13(9):1088-99 [18622704.001]
  • [Cites] Cell. 2008 Oct 3;135(1):49-60 [18854154.001]
  • [Cites] J Virol. 2009 Sep;83(18):9283-95 [19587052.001]
  • [Cites] AIDS. 2008 Nov 30;22(18):2429-39 [19005266.001]
  • (PMID = 20877624.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / R01-DA-04334; United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIDA NIH HHS / DA / R01-DA-12568; United States / NCRR NIH HHS / RR / M01 RR00425; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / U01-AI-35042; United States / NIDA NIH HHS / DA / R56 DA004334; United States / NIAID NIH HHS / AI / U01-AI-37613; United States / NIDA NIH HHS / DA / R01 DA004334; United States / NIAID NIH HHS / AI / U1-AI-35041; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / U01-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CP / N02-CP-55504; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NCI NIH HHS / CP / N02CP55504; United States / NICHD NIH HHS / HD / R01 HD041224; United States / NIAID NIH HHS / AI / U01-AI-35040; United States / PHS HHS / / HHSN261200800001E; United States / NCRR NIH HHS / RR / M01 RR000425; United States / NIAID NIH HHS / AI / U01-AI-37984; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIDA NIH HHS / DA / R01 DA012568; United States / NIAID NIH HHS / AI / U01-AI-35039; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCI NIH HHS / CA / N01CO12400; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CA / HHSN261200800001E; United States / NICHD NIH HHS / HD / 1 R01 HD41224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2943476
  •  go-up   go-down


3. Johnson AS, Maronian N, Vieira J: Activation of Kaposi's sarcoma-associated herpesvirus lytic gene expression during epithelial differentiation. J Virol; 2005 Nov;79(21):13769-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of Kaposi's sarcoma-associated herpesvirus lytic gene expression during epithelial differentiation.
  • The oral cavity has been identified as the major site for the shedding of infectious Kaposi's sarcoma-associated herpesvirus (KSHV).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Differentiation. 1990 Dec;45(3):230-41 [1708735.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1991 May;100(5 Pt 1):372-7 [1708954.001]
  • [Cites] J Virol. 1991 Jun;65(6):2868-74 [1851858.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1369-80 [1661074.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):347-50 [1312681.001]
  • [Cites] Science. 1992 Aug 14;257(5072):971-3 [1323879.001]
  • [Cites] J Virol. 1992 Oct;66(10):6070-80 [1326657.001]
  • [Cites] Cell Growth Differ. 1992 Aug;3(8):471-83 [1390334.001]
  • [Cites] Am J Pathol. 1993 Feb;142(2):403-12 [7679549.001]
  • [Cites] J Cell Biol. 1993 Jul;122(2):417-29 [8320264.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8479-83 [8397406.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 May 20;12(8):651-7 [8744575.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1996;253(4-5):245-51 [8737778.001]
  • [Cites] Acta Derm Venereol. 1996 May;76(3):177-81 [8800294.001]
  • [Cites] Clin Infect Dis. 1996 Aug;23(2):406-7 [8842293.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):94-102 [9207354.001]
  • [Cites] J Virol. 1997 Sep;71(9):7083-7 [9261440.001]
  • [Cites] J Med Virol. 1997 Sep;53(1):81-4 [9298737.001]
  • [Cites] J Invest Dermatol. 1997 Oct;109(4):501-9 [9326381.001]
  • [Cites] Arch Dermatol Res. 1997 Nov;289(12):677-85 [9452888.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Dec;29(12):1313-23 [9570130.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] Curr Clin Top Infect Dis. 1998;18:237-51 [9779358.001]
  • [Cites] J Infect Dis. 1999 Jan;179(1):234-6 [9841845.001]
  • [Cites] Oral Dis. 2001 Jul;7(4):252-8 [11575877.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(29):7-15 [11694559.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):749-52 [11745472.001]
  • [Cites] Clin Infect Dis. 2002 Feb 1;34(3):309-17 [11774077.001]
  • [Cites] JAMA. 2002 Jan 9;287(2):221-5 [11779265.001]
  • [Cites] Rev Med Virol. 2002 Jan-Feb;12(1):47-63 [11787083.001]
  • [Cites] Histol Histopathol. 2002 Jan;17(1):151-63 [11813865.001]
  • [Cites] JAMA. 2002 Mar 13;287(10):1295-300 [11886321.001]
  • [Cites] Bioessays. 2002 Sep;24(9):789-800 [12210515.001]
  • [Cites] Cell. 2002 Nov 1;111(3):369-79 [12419247.001]
  • [Cites] J Gen Virol. 2002 Dec;83(Pt 12):2995-8 [12466475.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2003 Feb;270(2):162-74 [12524691.001]
  • [Cites] Eur J Oral Sci. 2003 Feb;111(1):34-41 [12558806.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] Plast Reconstr Surg. 2003 Sep;112(3):784-92 [12960859.001]
  • [Cites] J Virol. 2003 Nov;77(21):11425-35 [14557628.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1142-8 [15004066.001]
  • [Cites] J Virol. 2004 Apr;78(8):4074-84 [15047824.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):233-8 [15076237.001]
  • [Cites] J Infect Dis. 2004 Jun 15;189(12):2260-70 [15181574.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):13-22 [15191537.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] Cell. 1975 Nov;6(3):331-43 [1052771.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):132-6 [9854077.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):399-404 [9927053.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 3;91(5):465-9 [10070947.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):189-92 [10188717.001]
  • [Cites] Br J Dermatol. 1984 Jul;111 Suppl 27:219-22 [6743553.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Exp Cell Res. 1986 Jan;162(1):114-26 [2415380.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Ann N Y Acad Sci. 1985;455:241-58 [2417515.001]
  • [Cites] J Invest Dermatol. 1986 Mar;86(3):249-54 [2427604.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1986 Aug;62(2):155-63 [2427985.001]
  • [Cites] J Cell Physiol. 1989 Aug;140(2):281-7 [2473084.001]
  • [Cites] Cell Tissue Kinet. 1989 Sep;22(5):361-75 [2611852.001]
  • [Cites] Differentiation. 1989 Sep;41(3):237-44 [2575553.001]
  • [Cites] J Infect Dis. 1999 Jun;179(6):1534-7 [10228077.001]
  • [Cites] J Virol. 1999 Aug;73(8):6566-72 [10400753.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] J Infect Dis. 1999 Sep;180(3):600-6 [10438345.001]
  • [Cites] Virology. 1999 Sep 15;262(1):237-49 [10489357.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):213-24 [10670545.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):702-4 [10682685.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1785-90 [10823785.001]
  • [Cites] Mol Pathol. 2000 Feb;53(1):37-42 [10884920.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1369-77 [11070101.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(5):2435-43 [11160746.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] Oral Oncol. 2001 Jul;37(5):419-30 [11377230.001]
  • [Cites] J Virol. 2001 Oct;75(20):10005-13 [11559836.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Clin Exp Dermatol. 1983 Jan;8(1):95-106 [6340868.001]
  • [Cites] J Cell Biol. 1983 Jul;97(1):244-51 [6190820.001]
  • [Cites] J Invest Dermatol. 1983 Jul;81(1 Suppl):2s-10s [6306115.001]
  • [Cites] N Engl J Med. 1984 May 10;310(19):1225-30 [6323983.001]
  • [Cites] J Cell Sci. 1990 Sep;97 ( Pt 1):39-50 [1701769.001]
  • (PMID = 16227296.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K23 AI051946; United States / NIDCR NIH HHS / DE / R01 DE014149; United States / NIAID NIH HHS / AI / AI51946-02; United States / NIDCR NIH HHS / DE / DE14149-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Precursors; 60108-77-2 / involucrin
  • [Other-IDs] NLM/ PMC1262565
  •  go-up   go-down


Advertisement
4. Orem J, Fu P, Ness A, Mwanda WO, Remick SC: Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease. East Afr Med J; 2005 Sep;82(9 Suppl):S144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease.
  • OBJECTIVES: To determine the effectiveness of an oral combination chemotherapy regimen administered to patients with AIDS-associated Hodgkin's disease.
  • CONCLUSIONS: This feasibility study demonstrates acceptable tolerance and excellent clinical activity of oral combination chemotherapy in patients with AIDS-associated Hodgkin's disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619690.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 6PLQ3CP4P3 / Etoposide; 7BRF0Z81KG / Lomustine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


5. Black SG, Arnaud F, Palmarini M, Spencer TE: Endogenous retroviruses in trophoblast differentiation and placental development. Am J Reprod Immunol; 2010 Oct;64(4):255-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ERVs have coevolved with their hosts for millions of years and are recognized to contribute to genome plasticity, protect the host against infection of related pathogenic and exogenous retroviruses, and play a vital role in development of the placenta.
  • This review will focus on the critical role of ERVs in development of the mammalian placenta and specifically highlight the biological role of sheep JSRV-related endogenous betaretroviruses in conceptus (embryo and associated extraembryonic membranes) development.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Placenta. 1999 Jan;20(1):109-18 [9950152.001]
  • [Cites] J Virol. 1999 Aug;73(8):6964-72 [10400795.001]
  • [Cites] Endocrinology. 1999 Sep;140(9):4070-80 [10465278.001]
  • [Cites] Proc Am Philos Soc. 2004 Sep;148(3):264-80 [15551500.001]
  • [Cites] Reproduction. 2004 Dec;128(6):657-68 [15579583.001]
  • [Cites] J Virol. 2005 Jan;79(2):927-33 [15613321.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):725-30 [15644441.001]
  • [Cites] J Virol. 2005 Apr;79(7):4440-50 [15767444.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):904-7 [15829964.001]
  • [Cites] Placenta. 2005 Apr;26 Suppl A:S21-30 [15837062.001]
  • [Cites] Physiology (Bethesda). 2005 Jun;20:180-93 [15888575.001]
  • [Cites] Biol Reprod. 2005 Aug;73(2):271-9 [15788753.001]
  • [Cites] Cytogenet Genome Res. 2005;110(1-4):318-32 [16093684.001]
  • [Cites] Anim Reprod Sci. 2006 Jul;93(3-4):185-98 [16043315.001]
  • [Cites] Virology. 2006 Jul 5;350(2):347-57 [16500691.001]
  • [Cites] Nature. 2006 Jul 6;442(7098):79-81 [16823453.001]
  • [Cites] J Comp Pathol. 2006 Jul;135(1):1-10 [16814801.001]
  • [Cites] J Virol. 2006 Aug;80(16):8030-7 [16873259.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14390-5 [16980413.001]
  • [Cites] Hum Reprod Update. 2007 Mar-Apr;13(2):121-41 [17068222.001]
  • [Cites] Reprod Fertil Dev. 2007;19(1):65-78 [17389136.001]
  • [Cites] PLoS Pathog. 2007 Nov;3(11):e170 [17997604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20534-9 [18077339.001]
  • [Cites] Virus Genes. 2008 Feb;36(1):147-55 [18176837.001]
  • [Cites] Annu Rev Genet. 2008;42:709-32 [18694346.001]
  • [Cites] Science. 2009 Apr 24;324(5926):532-6 [19390051.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):785-9 [10693809.001]
  • [Cites] J Virol. 2000 Apr;74(7):3321-9 [10708449.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 20;16(8):731-40 [10826480.001]
  • [Cites] J Virol. 2000 Sep;74(17):8065-76 [10933716.001]
  • [Cites] Curr Opin Genet Dev. 2000 Dec;10(6):651-5 [11088016.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4443-8 [11296287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4449-54 [11296288.001]
  • [Cites] J Virol. 2001 Nov;75(22):11002-9 [11602740.001]
  • [Cites] J Virol. 2001 Dec;75(23):11319-27 [11689612.001]
  • [Cites] J Gen Virol. 2002 Nov;83(Pt 11):2733-42 [12388809.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4580-5 [12676986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12127-32 [19564597.001]
  • [Cites] Ann N Y Acad Sci. 2009 Oct;1178:157-72 [19845636.001]
  • [Cites] Retrovirology. 2009;6:107 [19943933.001]
  • [Cites] Int J Cancer. 2010 Jan 15;126(2):306-14 [19795446.001]
  • [Cites] Mol Cell Biol. 2003 May;23(10):3566-74 [12724415.001]
  • [Cites] Virus Genes. 2003 May;26(3):291-315 [12876457.001]
  • [Cites] Virology. 2003 Jul 20;312(1):95-105 [12890624.001]
  • [Cites] J Virol. 2003 Oct;77(19):10414-22 [12970426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13013-8 [14557543.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Mar 25;2:15 [15043753.001]
  • [Cites] Placenta. 2004 Sep-Oct;25(8-9):673-83 [15450384.001]
  • [Cites] J Natl Cancer Inst. 1973 Apr;50(4):1081-4 [4703773.001]
  • [Cites] J Natl Cancer Inst. 1974 Mar;52(3):987-9 [4363698.001]
  • [Cites] Bibl Haematol. 1975;(40):391-401 [169817.001]
  • [Cites] Am J Anat. 1984 Jun;170(2):233-50 [6465051.001]
  • [Cites] Virology. 1985 Dec;147(2):449-58 [3840930.001]
  • [Cites] Hum Reprod. 1988 Apr;3(3):395-8 [2836475.001]
  • [Cites] FEBS Lett. 1991 Dec 16;295(1-3):3-4 [1765162.001]
  • [Cites] J Virol. 1992 Aug;66(8):4930-9 [1629959.001]
  • [Cites] Placenta. 1992 Mar-Apr;13(2):101-13 [1631024.001]
  • [Cites] J Exp Zool. 1993 Sep 1;266(6):559-77 [8371098.001]
  • [Cites] Virology. 1993 Oct;196(2):905-9 [8372456.001]
  • [Cites] J Reprod Fertil Suppl. 1995;49:39-51 [7623329.001]
  • [Cites] Virology. 1995 Aug 20;211(2):589-92 [7645262.001]
  • [Cites] J Virol. 1997 Feb;71(2):859-65 [8995601.001]
  • [Cites] J Virol. 1998 Apr;72(4):3442-5 [9525678.001]
  • [Cites] Bioessays. 1998 Apr;20(4):307-16 [9619102.001]
  • [Cites] J Virol. 1998 Jul;72(7):5955-66 [9621058.001]
  • [Cites] J Gen Virol. 1998 Nov;79 ( Pt 11):2687-94 [9820144.001]
  • (PMID = 20528833.001).
  • [ISSN] 1600-0897
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0801822; United States / NICHD NIH HHS / HD / R01 HD052745; United States / NICHD NIH HHS / HD / HD052745; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Other-IDs] NLM/ NIHMS634036; NLM/ PMC4198168
  •  go-up   go-down


6. Palefsky JM: Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol; 2009 Sep;21(5):433-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer prevention in HIV-positive men and women.
  • PURPOSE OF REVIEW: The incidence of human papillomavirus-associated anal cancer is unacceptably high among HIV-positive men who have sex with men, and possibly in HIV-positive women.
  • Unlike most other malignancies occurring in the HIV-positive population, anal cancer is potentially preventable, using methods similar to those used to prevent cervical cancer in women.
  • This review discusses the issues around screening to prevent anal cancer.
  • RECENT FINDINGS: Recent studies show that the incidence of anal cancer has increased since the introduction of highly active antiretroviral therapy in this population and now exceeds the highest incidence of cervical cancer among women reported anywhere in the world.
  • SUMMARY: The high incidence of anal cancer among HIV-positive individuals must not be ignored, since it may be preventable.
  • Given the current evidence and analogy with the cervical cancer prevention model, many clinicians believe that identification and treatment of high-grade anal intraepithelial neoplasia to prevent anal cancer are warranted.
  • When the expertise to do so exists, this is a reasonable approach, particularly if coupled with efforts to optimize further screening and treatment approaches, as well as efforts to document the efficacy of high-grade anal intraepithelial neoplasia treatment to reduce the incidence of anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):474-9 [19779306.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] Dis Colon Rectum. 2009 Feb;52(2):239-47 [19279418.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207; quiz CE1-4 [19357635.001]
  • [Cites] Br J Dermatol. 2009 Oct;161(4):904-9 [19466962.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • (PMID = 19587592.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCI NIH HHS / CA / CA088739-04S2; United States / NCI NIH HHS / CA / CA054053-10; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA088739-04S2; United States / NCRR NIH HHS / RR / M01 RR00079; United States / NCI NIH HHS / CA / R01CA 88739; United States / NCI NIH HHS / CA / R01 CA054053-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  • [Other-IDs] NLM/ NIHMS202771; NLM/ PMC3415247
  •  go-up   go-down


7. Chandwani S, Wentworth C, Burke TA, Patterson TF: Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice. Curr Med Res Opin; 2009 Feb;25(2):385-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mixed multivariable models were developed to identify factors associated with mean daily dose.
  • Micafungin patients had the highest prevalence of cancer, bone marrow transplant, solid organ transplant, HIV/AIDS, fungal infection, and neutropenia.
  • The first-day dose of echinocandin therapy (vs. subsequent days) was most strongly associated with mean daily dose.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192983.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins
  •  go-up   go-down


8. Ginzburg K: Life events and adjustment following myocardial infarction: a longitudinal study. Soc Psychiatry Psychiatr Epidemiol; 2006 Oct;41(10):825-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Although pre-MI life events were associated with both ASD and PTSD symptom severity, the relation between these events and PTSD was mediated by ASD.
  • DISCUSSION: These findings emphasize the fact that traumatic events do not occur in isolation and that their emotional impact is related to other events that occur both before and after.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Psychiatry. 1994 Jun;151(6):888-94 [8184999.001]
  • [Cites] Int J Emerg Ment Health. 2004 Winter;6(1):5-14 [15131998.001]
  • [Cites] Am J Psychiatry. 1998 Nov;155(11):1565-9 [9812119.001]
  • [Cites] J Pers Soc Psychol. 2003 Mar;84(3):632-43 [12635922.001]
  • [Cites] Am Psychol. 1989 Mar;44(3):513-24 [2648906.001]
  • [Cites] J Pers Soc Psychol. 1998 Feb;74(2):420-34 [9491585.001]
  • [Cites] J Trauma Stress. 1997 Apr;10(2):215-34 [9136089.001]
  • [Cites] J Womens Health (Larchmt). 2004 Apr;13(3):315-24 [15130260.001]
  • [Cites] Circulation. 2000 Mar 7;101(9):969-74 [10704162.001]
  • [Cites] Br J Clin Psychol. 1999 Nov;38 ( Pt 4):411-6 [10590829.001]
  • [Cites] Am J Psychiatry. 1999 Mar;156(3):360-6 [10080549.001]
  • [Cites] J Trauma Stress. 2000 Jan;13(1):115-28 [10761178.001]
  • [Cites] Circulation. 1997 Mar 18;95(6):1402-10 [9118506.001]
  • [Cites] Psychosom Med. 2005 May-Jun;67(3):359-65 [15911897.001]
  • [Cites] Psychol Med. 1995 Nov;25(6):1289-94 [8637958.001]
  • [Cites] Psychiatry Res. 2001 Dec 15;105(1-2):1-12 [11740970.001]
  • [Cites] AIDS Patient Care STDS. 2005 Feb;19(2):110-20 [15716642.001]
  • [Cites] Lancet. 2004 Sep 11-17;364(9438):953-62 [15364186.001]
  • [Cites] J Nerv Ment Dis. 1999 Jul;187(7):443-6 [10426466.001]
  • [Cites] Am J Psychiatry. 1996 Feb;153(2):219-25 [8561202.001]
  • [Cites] Am J Psychiatry. 2005 Dec;162(12):2309-14 [16330595.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 1989 Jan;24(1):41-8 [2496477.001]
  • [Cites] Soc Sci Med. 2005 Sep;61(6):1267-77 [15970236.001]
  • [Cites] Isr J Psychiatry Relat Sci. 1994;31(1):48-56 [8206738.001]
  • [Cites] JAMA. 1997 Feb 12;277(6):461-6 [9020269.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):679-89 [12910510.001]
  • [Cites] Acta Psychiatr Scand. 2004 Dec;110(6):421-9 [15521826.001]
  • [Cites] Isr J Psychiatry Relat Sci. 1993;30(2):110-5 [8270385.001]
  • [Cites] Psychother Psychosom. 2005;74(3):179-84 [15832069.001]
  • [Cites] J Psychosom Res. 2004 Dec;57(6):583-7 [15596165.001]
  • [Cites] Am J Psychiatry. 1998 May;155(5):625-9 [9585713.001]
  • [Cites] J Clin Psychiatry. 2003 Oct;64(10):1217-23 [14658971.001]
  • [Cites] Soc Sci Med. 1988;26(3):319-25 [3347854.001]
  • [Cites] J Trauma Stress. 1998 Jan;11(1):87-101 [9479678.001]
  • [Cites] Gen Hosp Psychiatry. 1994 May;16(3):193-9 [8063086.001]
  • [Cites] J Consult Clin Psychol. 1998 Jun;66(3):507-12 [9642889.001]
  • [Cites] Psychosom Med. 2004 Jul-Aug;66(4):521-6 [15272097.001]
  • [Cites] Soc Sci Med. 2000 May;50(10):1475-84 [10741582.001]
  • [Cites] J Cardiopulm Rehabil. 2005 May-Jun;25(3):166-72 [15931021.001]
  • [Cites] Heart Lung. 2003 Sep-Oct;32(5):300-7 [14528187.001]
  • [Cites] J Pers Soc Psychol. 1986 Dec;51(6):1173-82 [3806354.001]
  • [Cites] N Engl J Med. 1996 Apr 4;334(14):884-90 [8596571.001]
  • (PMID = 16896517.001).
  • [ISSN] 0933-7954
  • [Journal-full-title] Social psychiatry and psychiatric epidemiology
  • [ISO-abbreviation] Soc Psychiatry Psychiatr Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


9. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK: Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol; 2007 Jul;81(13):7099-110
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the decrease in plus-strand DNA transfer did not account for all of the observed decrease in viral DNA synthesis associated with A3G.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Aug;74(15):7039-47 [10888643.001]
  • [Cites] Nature. 2003 Jul 3;424(6944):94-8 [12808465.001]
  • [Cites] J Virol. 2001 Jul;75(14):6537-46 [11413321.001]
  • [Cites] Genomics. 2002 Mar;79(3):285-96 [11863358.001]
  • [Cites] Nature. 2002 Aug 8;418(6898):646-50 [12167863.001]
  • [Cites] Nature. 2002 Sep 5;419(6902):43-8 [12214226.001]
  • [Cites] J Virol. 2003 Jan;77(2):1131-40 [12502829.001]
  • [Cites] J Virol. 2003 Jan;77(2):1469-80 [12502862.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):7902-9 [12458216.001]
  • [Cites] Science. 2003 May 16;300(5622):1112 [12750511.001]
  • [Cites] Nature. 2003 Jul 3;424(6944):99-103 [12808466.001]
  • [Cites] Cell. 2003 Jul 11;114(1):21-31 [12859895.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44412-6 [12970355.001]
  • [Cites] Science. 2003 Nov 7;302(5647):1056-60 [14564014.001]
  • [Cites] Curr Biol. 2003 Nov 11;13(22):2009-13 [14614829.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):7792-8 [14672928.001]
  • [Cites] J Virol. 2004 Apr;78(7):3210-22 [15016842.001]
  • [Cites] J Mol Biol. 2004 Mar 26;337(3):585-96 [15019779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7 [15054139.001]
  • [Cites] J Virol. 2004 May;78(10):5402-13 [15113919.001]
  • [Cites] Nat Struct Mol Biol. 2004 May;11(5):435-42 [15098018.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28419-25 [15096517.001]
  • [Cites] J Virol. 2004 Aug;78(16):8761-70 [15280484.001]
  • [Cites] Curr Biol. 2004 Aug 10;14(15):1385-91 [15296757.001]
  • [Cites] Cell. 1982 Oct;30(3):797-805 [6183006.001]
  • [Cites] J Biol Chem. 1989 Jan 15;264(2):1163-71 [2492016.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6019-23 [2201018.001]
  • [Cites] J Virol. 1991 Apr;65(4):1779-88 [2002543.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):15071-9 [1378844.001]
  • [Cites] J Virol. 1993 Aug;67(8):4945-55 [8331734.001]
  • [Cites] AIDS Res Hum Retroviruses. 1993 Sep;9(9):833-8 [7504935.001]
  • [Cites] J Virol. 1996 Aug;70(8):5297-305 [8764040.001]
  • [Cites] J Virol. 1999 Feb;73(2):1682-8 [9882380.001]
  • [Cites] Adv Virus Res. 1999;52:427-58 [10384246.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):166-70 [15668174.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):479-90 [15721252.001]
  • [Cites] Virology. 2005 Mar 15;333(2):374-86 [15721369.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):10920-4 [15647250.001]
  • [Cites] Virology. 2005 Apr 10;334(2):147-53 [15780864.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):18573-8 [15781449.001]
  • [Cites] J Virol. 2005 Sep;79(17):10978-87 [16103149.001]
  • [Cites] J Virol. 2005 Oct;79(19):12584-91 [16160186.001]
  • [Cites] J Virol. 2006 Jan;80(2):875-82 [16378989.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):41-6 [16418394.001]
  • [Cites] Nat Struct Mol Biol. 2006 May;13(5):392-9 [16622407.001]
  • [Cites] J Virol. 2006 Aug;80(15):7645-57 [16840343.001]
  • [Cites] J Virol. 2006 Sep;80(17):8450-8 [16912295.001]
  • [Cites] Virology. 2006 Sep 15;353(1):41-51 [16784767.001]
  • [Cites] J Virol. 2006 Dec;80(23):11710-22 [16971427.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2587-95 [17121840.001]
  • [Cites] Virology. 2007 Apr 10;360(2):247-56 [17126871.001]
  • [Cites] Cell. 2003 Jun 13;113(6):803-9 [12809610.001]
  • [Cites] Nat Immunol. 2003 Jul;4(7):641-3 [12830140.001]
  • [Cites] Nat Med. 2001 May;7(5):631-4 [11329067.001]
  • (PMID = 17428871.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R29 GM056615; United States / NIAID NIH HHS / AI / R37 AI064046; United States / NIAID NIH HHS / AI / R37 AI039394; United States / NIAID NIH HHS / AI / R01 AI039394; United States / NIGMS NIH HHS / GM / GM56615; United States / Intramural NIH HHS / / ; United States / NIAID NIH HHS / AI / AI064046; United States / NCI NIH HHS / CO / N01-CO12400; United States / NIAID NIH HHS / AI / R56 AI064046; United States / NIAID NIH HHS / AI / AI39394; United States / NIAID NIH HHS / AI / K02 AI057735; United States / NCI NIH HHS / CA / N01CO12400; United States / NIGMS NIH HHS / GM / R01 GM056615; United States / NIAID NIH HHS / AI / R01 AI064046; United States / NIAID NIH HHS / AI / AI57735
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Viral; 0 / Gene Products, vif; 0 / Repressor Proteins; 0 / vif Gene Products, Human Immunodeficiency Virus; 9014-25-9 / RNA, Transfer; EC 3.5.4.- / Nucleoside Deaminases; EC 3.5.4.5 / APOBEC3G protein, human; EC 3.5.4.5 / Cytidine Deaminase
  • [Other-IDs] NLM/ PMC1933301
  •  go-up   go-down


10. McQueen A, Swank PR, Bastian LA, Vernon SW: Predictors of perceived susceptibility of breast cancer and changes over time: a mixed modeling approach. Health Psychol; 2008 Jan;27(1):68-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of perceived susceptibility of breast cancer and changes over time: a mixed modeling approach.
  • OBJECTIVE: To examine predictors of perceived susceptibility to breast cancer and assess differences across three dependent measures.
  • Multivariable non-linear mixed model analyses examined individual- and group-level changes in perceived susceptibility to breast cancer.
  • DEPENDENT MEASURES: Three single-item measures of perceived susceptibility to breast cancer (percent risk, ordinal risk, and comparative risk likelihood).
  • RESULTS: Breast symptoms and greater cancer worry increased perceived susceptibility for all three measures.
  • CONCLUSION: Despite small model effect sizes, breast symptoms and cancer worry were consistent predictors and may be good targets for messages designed to influence women's perceived susceptibility to breast cancer.
  • Combining indicators of perceived susceptibility may be undesirable when different predictors are associated with different measures.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1999;(25):101-19 [10854465.001]
  • [Cites] AIDS Care. 2000 Jun;12(3):273-8 [10928203.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):973-5 [11008917.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):35-43 [11205487.001]
  • [Cites] J Stud Alcohol. 2001 Jan;62(1):105-13 [11271958.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):895-8 [11489757.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1373-8 [11986766.001]
  • [Cites] J Health Commun. 2004 Jan-Feb;9(1):53-65 [14761833.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):366-72 [15006910.001]
  • [Cites] Prev Med. 2004 Apr;38(4):388-402 [15020172.001]
  • [Cites] Health Psychol. 2004 May;23(3):247-58 [15099165.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):616-20 [15100339.001]
  • [Cites] J Behav Med. 2004 Apr;27(2):205-14 [15171107.001]
  • [Cites] Prev Med. 2004 Jul;39(1):64-73 [15207987.001]
  • [Cites] Health Educ Q. 1984 Spring;11(1):1-47 [6392204.001]
  • [Cites] Med Care. 1988 Jul;26(7):724-35 [3393032.001]
  • [Cites] Health Psychol. 1988;7(4):355-86 [3049068.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] Health Psychol. 1990;9(6):792-806 [2286186.001]
  • [Cites] Breast Cancer Res Treat. 1993 Nov;28(2):137-44 [8173066.001]
  • [Cites] Prev Med. 1994 May;23(3):302-8 [8078850.001]
  • [Cites] Health Psychol. 1994 Nov;13(6):526-38 [7889908.001]
  • [Cites] Health Psychol. 1996 Nov;15(6):423-9 [8973921.001]
  • [Cites] J Pers Soc Psychol. 1997 Jan;72(1):184-95 [9008380.001]
  • [Cites] Womens Health. 1995 Spring;1(1):27-50 [9373372.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):533-9 [10385144.001]
  • [Cites] Prev Med. 2005 May;40(5):489-501 [15749130.001]
  • [Cites] Prev Med. 2005 Jun;40(6):779-84 [15850879.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):229-37 [16034008.001]
  • [Cites] Health Psychol. 2005 Nov;24(6):555-66 [16287401.001]
  • [Cites] J Health Commun. 2006;11 Suppl 1:71-92 [16641075.001]
  • [Cites] J Health Commun. 2006 Jun;11(4):391-407 [16720537.001]
  • [Cites] J Natl Cancer Inst Monogr. 1999;(25):15-20 [10854451.001]
  • (PMID = 18230016.001).
  • [ISSN] 0278-6133
  • [Journal-full-title] Health psychology : official journal of the Division of Health Psychology, American Psychological Association
  • [ISO-abbreviation] Health Psychol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA076330-02; United States / NCI NIH HHS / CA / R01 CA076330-02; United States / NCI NIH HHS / CA / R01 CA076330; United States / NCI NIH HHS / CA / CA057712-11A1; United States / NCI NIH HHS / CA / R25CA57712-11; United States / NCI NIH HHS / CA / R25 CA057712; United States / NCI NIH HHS / CA / R25 CA057712-11A1; United States / NCI NIH HHS / CA / R01CA76330
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS171633; NLM/ PMC2819176
  •  go-up   go-down


11. McTiernan A, Whelan J, Leahy M, Woll PJ: A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma. Sarcoma; 2006;2006(1):41080
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In conclusion, DaunoXome at this dose and schedule is well tolerated in patients with advanced soft tissue sarcoma, but is not associated with significant activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):131-9 [10100273.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1634-9 [9862576.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):870-7 [11313175.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):457-62 [11398876.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):15-20 [12085249.001]
  • [Cites] J Chronic Dis. 1961 Apr;13:346-53 [13704181.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3255-61 [1596882.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4 Suppl 3):23-7 [6505714.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):996-1003 [7707129.001]
  • [Cites] Invest New Drugs. 1994;12(2):103-10 [7860226.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2353-64 [8708728.001]
  • [Cites] AIDS. 1996 Jun;10(7):753-7 [8805866.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):150-7 [10458228.001]
  • (PMID = 17040090.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC1510953
  •  go-up   go-down


12. Aiello-Laws L, Rutledge DN: Management of adult patients receiving intraventricular chemotherapy for the treatment of leptomeningeal metastasis. Clin J Oncol Nurs; 2008 Jun;12(3):429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer in the central nervous system can arise from a primary brain tumor and metastasize to the brain or to the leptomeninges, leading to leptomeningeal metastasis (LM).
  • Nursing care of patients with LM requires an understanding of neurologic anatomy and physiology, along with associated treatments and complications.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Blepharoptosis / etiology. Brain Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / nursing. Carcinoma / secondary. Drug Compounding. Drug Monitoring / nursing. Evidence-Based Medicine. Fatal Outcome. Humans. Low Back Pain / etiology. Lymphoma, AIDS-Related / complications. Male. Muscle Weakness / etiology. Nurse's Role. Nursing Assessment. Practice Guidelines as Topic

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515241.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  • [Number-of-references] 30
  •  go-up   go-down


13. Shaffer AL, Emre NC, Romesser PB, Staudt LM: IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res; 2009 May 1;15(9):2954-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IRF4: Immunity. Malignancy! Therapy?
  • IRF4 expression is also associated with many lymphoid malignancies, with recent evidence pointing to an essential role in multiple myeloma, a malignancy of plasma cells.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Nov 15;90(10):3984-95 [9354667.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4639-50 [9671474.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4736-44 [9794404.001]
  • [Cites] EMBO J. 1999 Feb 15;18(4):977-91 [10022840.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2713-22 [10453013.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4088-96 [15331443.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2573-81 [15728463.001]
  • [Cites] Adv Immunol. 2005;87:163-208 [16102574.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6333-8 [16155016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15989-94 [16236719.001]
  • [Cites] J Interferon Cytokine Res. 2005 Dec;25(12):770-9 [16375605.001]
  • [Cites] Immunol Rev. 2006 Apr;210:67-85 [16623765.001]
  • [Cites] Blood. 2006 May 15;107(10):4090-100 [16424392.001]
  • [Cites] Nature. 2006 May 4;441(7089):106-10 [16572121.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):773-82 [16767092.001]
  • [Cites] Immunity. 2006 Aug;25(2):225-36 [16919487.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6930-9 [17082608.001]
  • [Cites] J Exp Med. 2007 Mar 19;204(3):633-43 [17353367.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20065-9 [17502370.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):115-30 [17692804.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1837-48 [10601358.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Immunity. 2000 Feb;12(2):129-40 [10714679.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9773-81 [10734131.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1281-92 [10770796.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1613-22 [11080800.001]
  • [Cites] J Immunol. 2001 May 15;166(10):6104-11 [11342629.001]
  • [Cites] Immunity. 2001 Sep;15(3):375-85 [11567628.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):111-20 [11846982.001]
  • [Cites] J Exp Med. 2002 Apr 15;195(8):1003-12 [11956291.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5667-74 [12023365.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7337-50 [12242308.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):467-74 [12406087.001]
  • [Cites] Cancer Cell. 2007 Aug;12(2):131-44 [17692805.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):958-66 [17676043.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):280-92 [17785208.001]
  • [Cites] Cell. 2007 Sep 21;130(6):986-8 [17889643.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2123-32 [18032762.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1396-403 [17971486.001]
  • [Cites] Immunity. 2008 Mar;28(3):335-45 [18280186.001]
  • [Cites] Science. 2008 Mar 21;319(5870):1676-9 [18323416.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2815-24 [18285461.001]
  • [Cites] Annu Rev Immunol. 2008;26:535-84 [18303999.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2761-6 [18427148.001]
  • [Cites] J Virol. 2008 Jul;82(13):6251-8 [18417578.001]
  • [Cites] Nature. 2008 Jul 10;454(7201):226-31 [18568025.001]
  • [Cites] J Natl Cancer Inst Monogr. 2008;(39):25-31 [18647998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Trends Immunol. 2008 Oct;29(10):487-92 [18775669.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1204-10 [18758461.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15890-5 [18836070.001]
  • [Cites] Immunity. 2008 Dec 19;29(6):899-911 [19062315.001]
  • [Cites] Leukemia. 2009 Jan;23(1):10-24 [18843284.001]
  • [Cites] Genes Immun. 2009 Jan;10(1):93-9 [18818690.001]
  • [Cites] Hematol Oncol. 2009 Mar;27(1):23-30 [18759374.001]
  • [Cites] Leukemia. 2009 Mar;23(3):574-80 [18987657.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):63-72 [16380510.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):703-14 [16470246.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1812-6 [10557056.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1097-105 [12453417.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49238-46 [12374808.001]
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1703-8 [12832394.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Immunity. 2004 Jun;20(6):707-18 [15189736.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):541-52 [15229473.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):115-22 [15226356.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]
  • [Cites] J Exp Med. 2004 Jul 19;200(2):247-53 [15249594.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2849-57 [15242870.001]
  • [Cites] Mol Cell Biol. 1992 Jan;12(1):368-78 [1729611.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1622-5 [8456286.001]
  • [Cites] Genes Dev. 1995 Jun 1;9(11):1377-87 [7797077.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1283-94 [8657101.001]
  • [Cites] J Exp Med. 1996 Jul 1;184(1):203-14 [8691135.001]
  • [Cites] Genes Dev. 1996 Sep 15;10(18):2335-47 [8824592.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Blood. 1997 Feb 1;89(3):789-93 [9028309.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):9785-92 [9092512.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • (PMID = 19383829.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4
  • [Number-of-references] 87
  • [Other-IDs] NLM/ NIHMS161833; NLM/ PMC2790720
  •  go-up   go-down


14. Xu C, Lo A, Yammanuru A, Tallarico AS, Brady K, Murakami A, Barteneva N, Zhu Q, Marasco WA: Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One; 2010 Mar 10;5(3):e9625
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides the CA signal transduction activity, CAIX may serve as a biomarker in early stages of oncogenesis and also as a reliable marker of hypoxia, which is associated with tumor resistance to chemotherapy and radiotherapy.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 May 15;115(10 Suppl):2327-33 [19402069.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):304-10 [17395103.001]
  • [Cites] J Urol. 2000 Feb;163(2):408-17 [10647643.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4 [10688890.001]
  • [Cites] Int J Cancer. 2000 Mar 15;85(6):865-70 [10709109.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1928-35 [10784634.001]
  • [Cites] Br J Cancer. 2000 Jun;82(11):1808-13 [10839295.001]
  • [Cites] Nat Biotechnol. 2000 Jun;18(6):649-54 [10835604.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1607-20 [10959047.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):70-5 [11753365.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Lancet Oncol. 2003 Apr;4(4):215-23 [12681265.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2470-6 [12750268.001]
  • [Cites] Eur Urol. 2003 Jul;44(1):65-75 [12814677.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] J Immunol Methods. 2003 Nov;282(1-2):117-34 [14604546.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):985-90 [14997194.001]
  • [Cites] Proteomics. 2004 Jun;4(6):1633-49 [15174133.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5624-31 [15184875.001]
  • [Cites] Int J Cancer. 1986 Oct 15;38(4):489-94 [2428759.001]
  • [Cites] J Biol Chem. 1991 Jan 15;266(2):894-902 [1985970.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):598-609 [8080042.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] Genomics. 1996 May 1;33(3):480-7 [8661007.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91 [8811493.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Mol Med Today. 1999 Apr;5(4):172-7 [10203750.001]
  • [Cites] FEBS Lett. 2004 Nov 19;577(3):439-45 [15556624.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):7-15 [15598929.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] Nat Biotechnol. 2005 Jun;23(6):709-17 [15908939.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2935-47 [16310354.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] Can J Urol. 2006 Apr;13 Suppl 2:57-62 [16672131.001]
  • [Cites] Adv Clin Chem. 2006;42:167-216 [17131627.001]
  • [Cites] Kidney Int. 2007 Jan;71(2):103-15 [17164835.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):279-81 [17395099.001]
  • [Cites] Nucl Med Commun. 2002 Mar;23(3):229-36 [11891480.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2408-18 [17675502.001]
  • [Cites] Cancer Immun. 2007;7:13 [17705349.001]
  • [Cites] Cancer Immun. 2007;7:14 [17705350.001]
  • [Cites] Cancer Imaging. 2007;7:179-88 [18055291.001]
  • [Cites] Science. 2008 Aug 15;321(5891):974-7 [18703743.001]
  • [Cites] Cell. 2008 Aug 22;134(4):577-86 [18691745.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27799-809 [18703501.001]
  • [Cites] Int J Oncol. 2009 Mar;34(3):629-39 [19212667.001]
  • [Cites] Cancer. 2009 Apr 1;115(7):1448-58 [19195047.001]
  • [Cites] Cancer. 2009 May 15;115(10 Suppl):2247-51 [19402064.001]
  • (PMID = 20224781.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21DK072282; United States / NIAID NIH HHS / AI / R21AI058804; United States / NCI NIH HHS / CA / P50 CA101942; United States / NIAID NIH HHS / AI / R21 AI058804; United States / NIDDK NIH HHS / DK / R21 DK072282; United States / NCRR NIH HHS / RR / S10 RR023459; United States / NCRR NIH HHS / RR / 1S10RR23459-01; United States / NCI NIH HHS / CA / 5P50CA101942
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Peptide Library; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2835754
  •  go-up   go-down


15. Majerciak V, Pripuzova N, McCoy JP, Gao SJ, Zheng ZM: Targeted disruption of Kaposi's sarcoma-associated herpesvirus ORF57 in the viral genome is detrimental for the expression of ORF59, K8alpha, and K8.1 and the production of infectious virus. J Virol; 2007 Feb;81(3):1062-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted disruption of Kaposi's sarcoma-associated herpesvirus ORF57 in the viral genome is detrimental for the expression of ORF59, K8alpha, and K8.1 and the production of infectious virus.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) ORF57 regulates viral gene expression at the posttranscriptional level during viral lytic infection.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Jan;74(2):1038-44 [10623771.001]
  • [Cites] J Virol. 2003 May;77(10):5578-88 [12719550.001]
  • [Cites] AIDS. 2000 May 5;14(7):899-902 [10839602.001]
  • [Cites] J Virol. 2000 Dec;74(23):10920-9 [11069986.001]
  • [Cites] J Virol. 2001 Feb;75(3):1487-506 [11152521.001]
  • [Cites] J Virol. 2001 Mar;75(6):2921-8 [11222717.001]
  • [Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] EMBO J. 2001 Oct 15;20(20):5769-78 [11598019.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):6969-78 [11742974.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14547-56 [11832484.001]
  • [Cites] Rev Med Virol. 2003 May-Jun;13(3):173-84 [12740832.001]
  • [Cites] N Engl J Med. 1996 May 16;334(20):1292-7 [8609946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11883-8 [8876232.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Jun;71(6):4187-92 [9151804.001]
  • [Cites] J Virol. 1998 Jul;72(7):6228-32 [9621095.001]
  • [Cites] J Virol. 1998 Aug;72(8):6725-31 [9658120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Feb;73(2):1341-9 [9882339.001]
  • [Cites] J Virol. 1999 Feb;73(2):1438-46 [9882349.001]
  • [Cites] J Virol. 1999 Mar;73(3):1909-17 [9971770.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Prog Neurobiol. 1999 May;58(1):31-59 [10321796.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] Biochem J. 2005 Apr 15;387(Pt 2):295-308 [15537388.001]
  • [Cites] Blood. 2005 May 15;105(10):4028-34 [15687238.001]
  • [Cites] J Cell Biochem. 2005 Jul 1;95(4):698-711 [15880690.001]
  • [Cites] J Virol. 2005 Sep;79(17):10952-67 [16103147.001]
  • [Cites] J Clin Pharm Ther. 2005 Oct;30(5):417-21 [16164485.001]
  • [Cites] Virology. 2005 Sep 30;340(2):183-91 [16043206.001]
  • [Cites] J Virol. 2005 Nov;79(22):14207-21 [16254356.001]
  • [Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):38-51 [16397526.001]
  • [Cites] J Virol. 2006 Jun;80(11):5251-60 [16699005.001]
  • [Cites] J Virol. 2006 Jul;80(14):7037-51 [16809309.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28365-78 [16829516.001]
  • [Cites] J Virol. 2006 Dec;80(24):11968-81 [17020939.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37790-8 [12857728.001]
  • [Cites] J Virol. 2004 Mar;78(5):2609-14 [14963167.001]
  • [Cites] J Virol. 2004 Jun;78(12):6389-98 [15163732.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):33001-11 [15155762.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Virol. 2000 Apr;74(8):3586-97 [10729134.001]
  • (PMID = 17108026.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / K8.1 protein, Human herpesvirus 8; 0 / ORF59 protein, Human herpesvirus 8; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC1797518
  •  go-up   go-down


16. Jayadev S, Yun B, Nguyen H, Yokoo H, Morrison RS, Garden GA: The glial response to CNS HIV infection includes p53 activation and increased expression of p53 target genes. J Neuroimmune Pharmacol; 2007 Dec;2(4):359-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-associated dementia (HAD) is a chronic neuroinflammatory disease that remains an important clinical problem without available rational treatment.
  • We have also shown that microglia from p53-deficient mice fail to induce neurotoxicity in response to the HIV coat protein gp120 in a coculture system, supporting the hypothesis that p53 plays a pathogenic role in the chronic neuroinflammatory component of HIV-associated neurodegeneration.
  • We analyzed the extent and cell type specificity of p53 accumulation in subcortical white matter of ten AIDS patients that had previously been shown to demonstrate white matter p53 accumulation.
  • [MeSH-major] AIDS Dementia Complex / genetics. AIDS Dementia Complex / metabolism. Central Nervous System Infections / metabolism. Gene Expression Regulation, Viral / physiology. Neuroglia / metabolism. Neuroglia / virology. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 2001;103(1):203-18 [11311801.001]
  • [Cites] Am J Pathol. 1996 Sep;149(3):1027-53 [8780406.001]
  • [Cites] Neuron. 1996 Mar;16(3):675-86 [8785064.001]
  • [Cites] Cancer Lett. 2004 Jan 20;203(2):199-207 [14732228.001]
  • [Cites] N Engl J Med. 1995 Apr 6;332(14):934-40 [7877652.001]
  • [Cites] J Neurosci Res. 1997 Dec 1;50(5):798-808 [9418967.001]
  • [Cites] Neurology. 2003 Jan 28;60(2):307-14 [12552050.001]
  • [Cites] Dev Biol. 2006 May 15;293(2):358-69 [16581057.001]
  • [Cites] Brain Pathol. 1999 Apr;9(2):209-17 [10219738.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):851-8 [15865941.001]
  • [Cites] FASEB J. 2004 Jul;18(10):1141-3 [15155568.001]
  • [Cites] AIDS. 2000 Sep 8;14(13):1949-54 [10997399.001]
  • [Cites] Neurology. 1993 Nov;43(11):2230-7 [8232935.001]
  • [Cites] J Leukoc Biol. 1994 Sep;56(3):389-98 [8083614.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):745-52 [11409426.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):695-704 [16127150.001]
  • [Cites] Curr Opin Neurol. 2001 Jun;14(3):375-9 [11371763.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Jul 23;71(1):78-86 [10407189.001]
  • [Cites] J Alzheimers Dis. 2001 Feb;3(1):31-40 [12214070.001]
  • [Cites] Adv Neuroimmunol. 1995;5(3):335-58 [8748077.001]
  • [Cites] Semin Neurol. 1999;19(2):113-27 [10718533.001]
  • [Cites] Science. 1990 Dec 14;250(4987):1593-6 [2148832.001]
  • [Cites] Exp Neurol. 2006 Oct;201(2):349-58 [16814281.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):988-92 [16372019.001]
  • [Cites] Glia. 1993 Jan;7(1):102-10 [8423057.001]
  • [Cites] Nature. 2001 Apr 19;410(6831):988-94 [11309629.001]
  • [Cites] J Cell Physiol. 2002 Jul;192(1):1-15 [12115731.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:855-8 [15846379.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16202-12 [10821866.001]
  • [Cites] J Cell Physiol. 1999 Nov;181(2):231-9 [10497302.001]
  • [Cites] Neurobiol Aging. 2005 Mar;26(3):349-54 [15639313.001]
  • [Cites] J Neurosci. 2003 Sep 24;23(25):8682-91 [14507967.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12 ):6763-8 [10823891.001]
  • [Cites] J Neural Transm Suppl. 1999;57:87-97 [10666670.001]
  • [Cites] J Neurotrauma. 2004 Jun;21(6):754-74 [15253803.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 14;182(3):1201-7 [1540165.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1121-30 [7747806.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):39-44 [8528731.001]
  • [Cites] Nature. 1997 May 15;387(6630):299-303 [9153396.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2001 Aug;251(4):159-69 [11697580.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2769-73 [8464887.001]
  • [Cites] Neurochem Res. 2003 Jan;28(1):15-27 [12587660.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Brain Pathol. 1991 Apr;1(3):143-52 [1669703.001]
  • [Cites] J Neurosci. 1995 Nov;15(11):7712-26 [7472522.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Apr;25(2):123-33 [10216000.001]
  • [Cites] Toxicol Lett. 2003 Apr 4;139(2-3):199-206 [12628755.001]
  • [Cites] Nature. 1997 May 15;387(6630):296-9 [9153395.001]
  • [Cites] Arch Neurol. 2002 Dec;59(12):1930-6 [12470182.001]
  • [Cites] Lab Invest. 1998 Apr;78(4):401-11 [9564885.001]
  • [Cites] Development. 2004 Mar;131(6):1211-20 [14960496.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 17;232(2):418-21 [9125193.001]
  • [Cites] Ann Neurol. 1992 Sep;32(3):321-9 [1416802.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):195-210 [12744473.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1717-25 [15111318.001]
  • [Cites] Ann Neurol. 1993 Jul;34(1):65-70 [8517682.001]
  • [Cites] Science. 1996 Jul 5;273(5271):59-63 [8658196.001]
  • [Cites] Nat Neurosci. 2001 Jul;4(7):702-10 [11426226.001]
  • [Cites] Ann Neurol. 1995 Nov;38(5):755-62 [7486867.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1115-20 [11048806.001]
  • [Cites] Ann Neurol. 1991 Jun;29(6):651-7 [1909852.001]
  • [Cites] Cell Mol Life Sci. 2004 Apr;61(7-8):822-42 [15095006.001]
  • [Cites] J Neurovirol. 2000 May;6 Suppl 1:S38-43 [10871764.001]
  • [Cites] Oncogene. 1999 Nov 1;18(45):6145-57 [10557106.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8212-6 [10393974.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1650-3 [16728594.001]
  • [Cites] Science. 2000 Apr 21;288(5465):440-2 [10798979.001]
  • [Cites] Neurobiol Dis. 2000 Dec;7(6 Pt B):613-22 [11114260.001]
  • [Cites] J Neurovirol. 2004;10 Suppl 1:97-101 [14982746.001]
  • [Cites] Prog Neurobiol. 2004 Feb;72(2):111-27 [15063528.001]
  • [Cites] Glia. 2002 Nov;40(2):240-51 [12379911.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Oncogene. 2001 Mar 8;20(10):1212-9 [11313865.001]
  • [Cites] Ann Neurol. 1997 Dec;42(6):963-72 [9403489.001]
  • [Cites] Neurology. 1992 Aug;42(8):1472-6 [1641138.001]
  • [Cites] Ann Neurol. 2003 Nov;54(5):605-14 [14595650.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):1979-90 [8903316.001]
  • (PMID = 18040854.001).
  • [ISSN] 1557-1904
  • [Journal-full-title] Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  • [ISO-abbreviation] J Neuroimmune Pharmacol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS35533; United States / NICHD NIH HHS / HD / P30-HD02774; United States / NIA NIH HHS / AG / T32-AG000268; United States / NINDS NIH HHS / NS / NS45528; United States / NIMH NIH HHS / MH / U01 MH083545; United States / NIMH NIH HHS / MH / N01MH32002
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


17. Mitton-Fry RM, DeGregorio SJ, Wang J, Steitz TA, Steitz JA: Poly(A) tail recognition by a viral RNA element through assembly of a triple helix. Science; 2010 Nov 26;330(6008):1244-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus produces a highly abundant, nuclear noncoding RNA, polyadenylated nuclear (PAN) RNA, which contains an element that prevents its decay.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2010 Oct;10(10):707-19 [20865011.001]
  • [Cites] Mol Cell. 2010 Mar 12;37(5):597-606 [20227365.001]
  • [Cites] Nat Struct Biol. 2001 Apr;8(4):339-43 [11276255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4899-903 [11296253.001]
  • [Cites] RNA. 2001 Apr;7(4):499-512 [11345429.001]
  • [Cites] Nat Struct Mol Biol. 2004 Feb;11(2):121-7 [14749774.001]
  • [Cites] Biochim Biophys Acta. 2004 May 25;1678(2-3):67-84 [15157733.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] J Biomol Struct Dyn. 1992 Aug;10(1):141-52 [1418737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11883-8 [8876232.001]
  • [Cites] Biochim Biophys Acta. 1957 Dec;26(3):457-68 [13499402.001]
  • [Cites] Mol Cell. 2005 Mar 4;17(5):671-82 [15749017.001]
  • [Cites] EMBO J. 2005 May 18;24(10):1831-41 [15861127.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Mol Cell. 2006 Dec 28;24(6):943-53 [17189195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6655-60 [17412831.001]
  • [Cites] Mol Cell. 2007 Apr 27;26(2):205-15 [17466623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10412-7 [17563387.001]
  • [Cites] Nat Struct Mol Biol. 2008 Feb;15(2):177-82 [18204466.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Apr;9(4):337-44 [18334997.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):683-92 [18598933.001]
  • [Cites] J Mol Biol. 2008 Dec 31;384(5):1249-61 [18950640.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • (PMID = 21109672.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 3P22
  • [Grant] United States / NCI NIH HHS / CA / CA16038; United States / NCI NIH HHS / CA / P01 CA016038-38; United States / Howard Hughes Medical Institute / / ; United States / NIBIB NIH HHS / EB / P30 EB009998; United States / NIGMS NIH HHS / GM / P01 GM022778; United States / NCI NIH HHS / CA / P01 CA016038; United States / NIGMS NIH HHS / GM / GM022778; United States / NIGMS NIH HHS / GM / R01 GM026154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Nuclear; 0 / RNA, Untranslated; 0 / RNA, Viral; 0 / Regulatory Sequences, Ribonucleic Acid; 0 / Riboswitch; 24937-83-5 / Poly A
  • [Other-IDs] NLM/ NIHMS287168; NLM/ PMC3074936
  •  go-up   go-down


18. Sathekge M, Goethals I, Maes A, van de Wiele C: Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging; 2009 Jul;36(7):1176-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews currently available PET studies performed either to improve our understanding of the pathogenesis of HIV-1 infection or to assess the value of PET imaging in the clinical decision making of patients infected with HIV-1 presenting with AIDS-related opportunistic infections and malignancies.
  • In lipodystrophic HIV-infected patients, limited available data support the hypothesis that stavudine-related lipodystrophy is associated with increased glucose uptake by adipose tissue as a result of the metabolic stress of adipose tissue in response to highly active antiretroviral treatment (HAART).
  • Finally, in early AIDS-related dementia complex (ADC), striatal hypermetabolism is observed, whereas progressive ADC is characterized by a decrease in subcortical and cortical metabolism.
  • In the clinical setting, PET has been shown to allow the differentiation of AIDS-related opportunistic infections and malignancies, and to allow monitoring of side effects of HAART.
  • However, in patients suffering from HIV infection and presenting with extracerebral lymphoma or other human malignancies, knowledge of viraemia is essential when interpreting FDG PET imaging.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2008 Sep;33(9):610-4 [18716509.001]
  • [Cites] Int J STD AIDS. 1996 Aug-Sep;7(5):337-46 [8894823.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):959-61 [14511930.001]
  • [Cites] J Clin Invest. 2002 Nov;110(9):1319-27 [12417571.001]
  • [Cites] Curr HIV Res. 2004 Jan;2(1):61-78 [15053341.001]
  • [Cites] J Neuroimmunol. 2004 Dec;157(1-2):153-62 [15579293.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] Brain. 2001 Oct;124(Pt 10):2014-27 [11571219.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1993 Summer;5(3):316-21 [8369642.001]
  • [Cites] Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-189-94 [18646347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6425-30 [8692831.001]
  • [Cites] BMC Med. 2008 Oct 31;6:31 [18976462.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):180-7 [7626961.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):640-7 [19082590.001]
  • [Cites] Curr Opin Oncol. 2008 Sep;20(5):534-40 [19106656.001]
  • [Cites] Biomark Med. 2008;2(4):349-361 [19057654.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] Semin Immunol. 2008 Jun;20(3):187-95 [18620868.001]
  • [Cites] Adv Cancer Res. 2008;101:349-95 [19055948.001]
  • [Cites] HIV Med. 2004 Mar;5(2):67-73 [15012644.001]
  • [Cites] Neurology. 1999 Dec 10;53(9):2199-203 [10599809.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):171-84 [18097219.001]
  • [Cites] Lancet. 2001 Aug 11;358(9280):461-7 [11513911.001]
  • [Cites] Arch Pharm Res. 2002 Jun;25(3):215-28 [12135090.001]
  • [Cites] J Neurovirol. 2005 Aug;11(4):346-55 [16162478.001]
  • [Cites] Neuroimage. 2008 Aug 15;42(2):869-78 [18579413.001]
  • [Cites] Ann Neurol. 1987 Dec;22(6):700-6 [3501695.001]
  • [Cites] J S C Med Assoc. 2008 Oct;104(7):223-6 [19058735.001]
  • [Cites] Int Rev Psychiatry. 2008 Feb;20(1):25-31 [18240060.001]
  • [Cites] AIDS. 2004 Dec 3;18(18):2430-2 [15622321.001]
  • [Cites] J Neurovirol. 2006 Aug;12 (4):262-71 [16966217.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):945-50 [14511927.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):701-6 [11299829.001]
  • [Cites] J Infect Dis. 2008 May 15;197 Suppl 3:S294-306 [18447615.001]
  • [Cites] AIDS. 2006 Feb 28;20(4):495-503 [16470113.001]
  • [Cites] Magn Reson Med. 1993 Mar;29(3):317-26 [8450740.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2093-9 [10382692.001]
  • [Cites] J Nucl Med. 1995 Dec;36(12 ):2169-74 [8523099.001]
  • [Cites] Indian J Pathol Microbiol. 2005 Apr;48(2):151-60 [16758653.001]
  • [Cites] J Nucl Med. 1996 Jul;37(7):1133-41 [8965184.001]
  • [Cites] Drug Saf. 2000 Jul;23(1):57-76 [10915032.001]
  • [Cites] J Neuroimmune Pharmacol. 2006 Jun;1(2):117-26 [18040778.001]
  • [Cites] AIDS Patient Care STDS. 2008 Sep;22(9):695-700 [18793085.001]
  • [Cites] J Nucl Med. 1991 Sep;32(9):1725-9 [1880574.001]
  • [Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]
  • [Cites] Semin Nucl Med. 1990 Oct;20(4):353-63 [2237453.001]
  • [Cites] Curr HIV/AIDS Rep. 2006 Feb;3(1):5-12 [16522253.001]
  • [Cites] Brain. 2004 Nov;127(Pt 11):2452-8 [15319273.001]
  • [Cites] Virology. 2000 Sep 1;274(2):255-61 [10964769.001]
  • [Cites] Arch Neurol. 2000 Nov;57(11):1601-7 [11074792.001]
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):532-6 [7622678.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1854-61 [7562055.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9 [18627663.001]
  • [Cites] J Nucl Med. 1989 May;30(5):581-90 [2785582.001]
  • [Cites] Mol Med Today. 2000 Mar;6(3):108-11 [10689313.001]
  • [Cites] J Nucl Med. 1997 Oct;38(10 ):1575-83 [9379195.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):280-7 [1498579.001]
  • [Cites] Exp Cell Res. 1991 Apr;193(2):425-31 [2004656.001]
  • [Cites] J Nucl Med. 1996 Jul;37(7):1177-80 [8965193.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] Semin Nucl Med. 1998 Oct;28(4):352-8 [9800240.001]
  • (PMID = 19350235.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 63
  •  go-up   go-down


19. Costelli P, Reffo P, Penna F, Autelli R, Bonelli G, Baccino FM: Ca(2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol; 2005 Oct;37(10):2134-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Skeletal muscle wasting is a prominent feature of cachexia, a complex systemic syndrome that frequently complicates chronic diseases such as inflammatory and autoimmune disorders, cancer and AIDS.
  • Modulations of Ca(2+)-dependent proteolysis have been associated with muscle protein depletion in various pathological contexts and particularly with muscle dystrophies.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893952.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Muscle Proteins; 0 / Ubiquitins; EC 3.4.22.- / Calpain; EC 3.4.25.1 / Proteasome Endopeptidase Complex; SY7Q814VUP / Calcium
  • [Number-of-references] 128
  •  go-up   go-down


20. Van Duyne R, Pedati C, Guendel I, Carpio L, Kehn-Hall K, Saifuddin M, Kashanchi F: The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology; 2009 Aug 12;6:76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The implantation of uneducated human immune cells and associated tissue provided the basis for the SCID-hu Thy/Liv and hu-PBL-SCID models.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1999 Dec 3;13(17):2486-8 [10597797.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2002;71:91-147 [12102562.001]
  • [Cites] Clin Exp Immunol. 2002 Sep;129(3):411-9 [12197881.001]
  • [Cites] Curr Med Chem. 2002 Nov;9(21):1893-903 [12369874.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3175-82 [12384415.001]
  • [Cites] Drug Resist Updat. 2002 Dec;5(6):219-23 [12531178.001]
  • [Cites] Immunity. 2003 Jan;18(1):41-51 [12530974.001]
  • [Cites] J Leukoc Biol. 2003 Mar;73(3):407-16 [12629155.001]
  • [Cites] Nat Med. 2003 Jul;9(7):853-60 [12835705.001]
  • [Cites] AIDS. 2003 Jul 25;17(11):1597-604 [12853741.001]
  • [Cites] Nature. 2003 Jul 10;424(6945):213-9 [12853962.001]
  • [Cites] J Virol. 2003 Aug;77(16):8719-28 [12885891.001]
  • [Cites] Front Biosci. 2003 Sep 1;8:d1134-45 [12957818.001]
  • [Cites] New Microbiol. 2003 Oct;26(4):405-13 [14596353.001]
  • [Cites] AIDS Rev. 2003 Jul-Sep;5(3):172-7 [14598566.001]
  • [Cites] Curr HIV Res. 2003 Jan;1(1):15-29 [15043209.001]
  • [Cites] Science. 2004 Apr 2;304(5667):104-7 [15064419.001]
  • [Cites] Curr HIV Res. 2004 Apr;2(2):153-62 [15078179.001]
  • [Cites] AIDS Rev. 2004 Apr-Jun;6(2):79-88 [15332430.001]
  • [Cites] Nature. 1983 Feb 10;301(5900):527-30 [6823332.001]
  • [Cites] Science. 1983 May 20;220(4599):865-7 [6601823.001]
  • [Cites] Science. 1983 May 20;220(4599):868-71 [6189183.001]
  • [Cites] Nature. 1988 Sep 15;335(6187):256-9 [2970594.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1632-9 [2971269.001]
  • [Cites] Science. 1988 Nov 25;242(4882):1168-71 [2460924.001]
  • [Cites] Science. 1988 Dec 23;242(4886):1684-6 [3201256.001]
  • [Cites] J Immunol. 1990 Apr 15;144(8):2992-8 [1969880.001]
  • [Cites] EMBO J. 1990 May;9(5):1551-60 [2184033.001]
  • [Cites] Cell. 1990 Apr 20;61(2):213-22 [2331748.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1152-4 [2174574.001]
  • [Cites] Blood. 1991 May 15;77(10):2109-17 [1709368.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4523-7 [1903543.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Exp Med. 1992 Feb 1;175(2):503-16 [1346272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4 [1373493.001]
  • [Cites] J Acquir Immune Defic Syndr. 1992;5(7):639-46 [1613662.001]
  • [Cites] J Immunol. 1993 May 1;150(9):3817-24 [8473734.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3440-8 [8099506.001]
  • [Cites] Nature. 1993 Jun 24;363(6431):728-32 [8100043.001]
  • [Cites] Nature. 1993 Jun 24;363(6431):732-6 [8515816.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] J Exp Med. 1993 Oct 1;178(4):1151-63 [8376927.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2501-9 [8400297.001]
  • [Cites] Diabetes. 1993 Nov;42(11):1574-8 [8405697.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):513-22 [8294863.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):546-51 [8112890.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Feb;10(2):131-41 [8198867.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):180-91 [7995938.001]
  • [Cites] J Infect Dis. 1995 Oct;172(4):974-82 [7561218.001]
  • [Cites] Immunol Today. 1995 Nov;16(11):529-33 [7495490.001]
  • [Cites] Transplantation. 1995 Dec 15;60(11):1306-14 [8525526.001]
  • [Cites] J Virol. 1996 Jun;70(6):4038-44 [8648741.001]
  • [Cites] Nature. 1996 Aug 22;382(6593):722-5 [8751444.001]
  • [Cites] Semin Immunol. 1996 Aug;8(4):187-96 [8883141.001]
  • [Cites] Semin Immunol. 1996 Aug;8(4):223-31 [8883145.001]
  • [Cites] Semin Immunol. 1996 Aug;8(4):263-8 [8883150.001]
  • [Cites] Blood. 1996 Nov 15;88(10):3731-40 [8916937.001]
  • [Cites] J Virol. 1997 Mar;71(3):2417-24 [9032379.001]
  • [Cites] J Virol. 1998 Jun;72(6):4962-9 [9573265.001]
  • [Cites] J Virol. 1998 Jun;72(6):5121-7 [9573283.001]
  • [Cites] Stem Cells. 1998;16(3):166-77 [9617892.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):33-9 [9647878.001]
  • [Cites] J Biomed Sci. 1998 Jul-Aug;5(4):253-9 [9691217.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):335-42 [9827902.001]
  • [Cites] Immunity. 1999 Apr;10(4):431-8 [10229186.001]
  • [Cites] J Interferon Cytokine Res. 1999 May;19(5):533-41 [10386866.001]
  • [Cites] J Virol. 1999 Nov;73(11):9089-97 [10516015.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:743-50 [15569614.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3886-93 [15319293.001]
  • [Cites] Curr Pharm Des. 2004;10(32):4065-70 [15579088.001]
  • [Cites] Nat Immunol. 2005 May;6(5):430-2 [15843796.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1093-7 [15793563.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 May;21(5):343-57 [15929696.001]
  • [Cites] Trends Microbiol. 2005 Jun;13(6):269-77 [15936659.001]
  • [Cites] Curr Drug Targets Infect Disord. 2005 Jun;5(2):193-201 [15975024.001]
  • [Cites] Curr Opin Immunol. 2005 Aug;17(4):366-73 [15955686.001]
  • [Cites] Antivir Ther. 1999;4 Suppl 3:13-8 [16021866.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] J Allergy Clin Immunol. 2005 Aug;116(2):419-22 [16083799.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1565-73 [15920010.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):90-7 [16002138.001]
  • [Cites] Virology. 2006 Jan 5;344(1):88-93 [16364740.001]
  • [Cites] J Immunol. 2006 Feb 15;176(4):2053-8 [16455958.001]
  • [Cites] Curr HIV/AIDS Rep. 2006 Feb;3(1):5-12 [16522253.001]
  • [Cites] Clin Dev Immunol. 2005 Dec;12(4):235-42 [16584108.001]
  • [Cites] J Virol. 2006 Nov;80(21):10683-91 [16943297.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15951-6 [17038503.001]
  • [Cites] Retrovirology. 2006;3:76 [17078891.001]
  • [Cites] AIDS. 2007 Jan 2;21(1):1-11 [17148962.001]
  • [Cites] Nat Med. 2006 Dec;12(12):1365-71 [17115046.001]
  • [Cites] Blood. 2007 Jan 1;109(1):212-8 [16954502.001]
  • [Cites] J Virol. 2007 Jan;81(2):599-612 [17065209.001]
  • [Cites] Nat Rev Microbiol. 2007 Feb;5(2):95-106 [17224919.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):118-30 [17259968.001]
  • [Cites] J Virol. 2007 Mar;81(6):2700-12 [17182671.001]
  • [Cites] Curr HIV/AIDS Rep. 2007 Feb;4(1):10-5 [17338855.001]
  • [Cites] Lancet Infect Dis. 2007 Apr;7(4):266-81 [17376384.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):133-40 [17387298.001]
  • [Cites] Clin Vaccine Immunol. 2007 Apr;14(4):391-6 [17314230.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2978-81 [17132723.001]
  • [Cites] PLoS One. 2007;2(7):e655 [17668043.001]
  • [Cites] Retrovirology. 2007;4:53 [17655755.001]
  • [Cites] Int J Hematol. 2007 Aug;86(2):101-6 [17875521.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2205-11 [17657714.001]
  • [Cites] Cancer Lett. 2007 Nov 18;257(2):206-15 [17764832.001]
  • [Cites] J Virol. 2007 Dec;81(23):13259-64 [17881441.001]
  • [Cites] Int Rev Immunol. 2007 Sep-Dec;26(5-6):249-68 [18027200.001]
  • [Cites] PLoS One. 2007;2(11):e1251 [18043758.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11859-66 [18089816.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] PLoS Med. 2008 Jan 15;5(1):e16 [18198941.001]
  • [Cites] Expert Rev Vaccines. 2008 Feb;7(1):117-30 [18251698.001]
  • [Cites] J Exp Med. 1999 Dec 20;190(12):1857-68 [10601360.001]
  • [Cites] Microbes Infect. 2000 Feb;2(2):223-9 [10742694.001]
  • [Cites] J Virol. 2000 Sep;74(18):8726-31 [10954574.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Dec 1;25(4):289-95 [11114828.001]
  • [Cites] J Virol. 2001 May;75(9):4420-3 [11287593.001]
  • [Cites] AIDS. 2001 Nov 23;15(17):2231-8 [11698695.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):561-7 [12007504.001]
  • [Cites] Curr HIV Res. 2008 Jan;6(1):1-9 [18288969.001]
  • [Cites] Int Rev Immunol. 2008 Jan-Apr;27(1-2):71-8 [18300056.001]
  • [Cites] Retrovirology. 2008;5:5 [18205925.001]
  • [Cites] Virology. 2008 Apr 10;373(2):342-51 [18207484.001]
  • [Cites] Cancer Sci. 2008 May;99(5):872-8 [18312467.001]
  • [Cites] AIDS Rev. 2008 Jan-Mar;10(1):36-46 [18385779.001]
  • [Cites] Vet Immunol Immunopathol. 2008 May 15;123(1-2):65-80 [18295907.001]
  • [Cites] Virus Res. 2008 Jun;134(1-2):104-23 [18289713.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;324:25-51 [18481451.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;324:53-76 [18481452.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;324:133-48 [18481458.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;324:149-65 [18481459.001]
  • [Cites] Retrovirology. 2008;5:34 [18426605.001]
  • [Cites] Retrovirology. 2008;5:37 [18439275.001]
  • [Cites] Virology. 2008 Jul 5;376(2):308-22 [18455747.001]
  • [Cites] Retrovirology. 2008;5:46 [18541021.001]
  • [Cites] J Virol. 2008 Oct;82(19):9359-68 [18653454.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2858-68 [18544681.001]
  • [Cites] Retrovirology. 2008;5:58 [18611257.001]
  • [Cites] J Virol. 2008 Dec;82(24):12145-53 [18842716.001]
  • [Cites] J Biol Chem. 2008 Dec 5;283(49):34045-52 [18809675.001]
  • [Cites] Mucosal Immunol. 2008 Jan;1(1):23-30 [19079157.001]
  • [Cites] Gene Ther. 2009 Jan;16(1):148-53 [18668146.001]
  • [Cites] Curr HIV Res. 2009 Jan;7(1):2-11 [19149549.001]
  • [Cites] Curr HIV/AIDS Rep. 2009 Feb;6(1):13-9 [19149992.001]
  • [Cites] Retrovirology. 2009;6:2 [19144136.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1287-93 [18948574.001]
  • [Cites] Retrovirology. 2009;6:19 [19228429.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Mar;4(2):125-30 [19339951.001]
  • [Cites] J Virol. 2009 Jun;83(12):6222-33 [19369341.001]
  • [Cites] Nature. 2009 Jul 23;460(7254):515-9 [19626114.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):888-902 [7717456.001]
  • [Cites] Biol Blood Marrow Transplant. 1996 Feb;2(1):15-23 [9078350.001]
  • [Cites] J Immunol. 1997 Apr 15;158(8):3578-86 [9103418.001]
  • [Cites] Nature. 1997 May 8;387(6629):183-8 [9144289.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1102-9 [9334721.001]
  • [Cites] J Virol. 1997 Nov;71(11):8456-66 [9343202.001]
  • [Cites] J Infect Dis. 1998 Apr;177(4):889-97 [9534960.001]
  • [Cites] J Immunol. 1998 Jan 1;160(1):69-76 [9551957.001]
  • (PMID = 19674458.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R21 AI071903; United States / NIAID NIH HHS / AI / AI071903-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Rag2 protein, mouse
  • [Number-of-references] 163
  • [Other-IDs] NLM/ PMC2743631
  •  go-up   go-down


21. Börner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, Höllt V, Kraus J: Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J Immunol; 2009 Jul 15;183(2):882-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, their use may complicate treatment of persons with an already impaired immune system, e.g., patients suffering from cancer or AIDS.
  • This in turn activated protein kinase A, which augmented the kinase activity of C-terminal Src kinase bound to phosphoprotein associated with glycosphingolipid-enrich microdomains, resulting in a further enhancement of the tonic inhibition of the leukocyte-specific protein tyrosine kinase Lck, thereby blocking the initiation of TCR signaling.

  • Hazardous Substances Data Bank. MORPHINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561113.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Opioid, mu; 0 / Transcription Factors; 60617-12-1 / beta-Endorphin; 76I7G6D29C / Morphine
  •  go-up   go-down


22. Gao L, Zhou F, Li X, Yang Y, Ruan Y, Jin Q: Anal HPV infection in HIV-positive men who have sex with men from China. PLoS One; 2010;5(12):e15256
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Anal HPV infection, which contributes to the development of anal warts and anal cancer, is well known to be common among men who have sex with men (MSM), especially among those HIV positives.
  • Anal HPV infection was found to be independently associated with increased HIV seropositivity, which suggests the application of HPV vaccine might be a potential strategy to reduce the acquisition of HIV infection though controlling the prevalence of HPV.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2000 Aug;27(4):471-9 [10950374.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):39-47 [15714063.001]
  • [Cites] Sex Transm Infect. 2001 Aug;77(4):248-54 [11463923.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 [15840880.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Lancet Infect Dis. 2006 Jan;6(1):21-31 [16377531.001]
  • [Cites] Vaccine. 2006 Mar 30;24 Suppl 1:S1-15 [16406226.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Sex Transm Infect. 2008 Aug;84(4):306-11 [18385223.001]
  • [Cites] Int J Oncol. 2008 Oct;33(4):777-82 [18813791.001]
  • [Cites] Curr Opin Infect Dis. 2009 Apr;22(2):109-14 [19276878.001]
  • [Cites] J Infect Dis. 2009 Apr 1;199(7):965-73 [19239366.001]
  • [Cites] Sex Transm Infect. 2009 Apr;85(2):148-9 [19153110.001]
  • [Cites] Obstet Gynecol Clin North Am. 2009 Mar;36(1):187-200 [19344856.001]
  • [Cites] AIDS. 2009 Jun 1;23(9):1135-42 [19390418.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1986-92 [19567510.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):330-5 [19342375.001]
  • [Cites] Sex Transm Infect. 2009 Sep;85(5):354-8 [19351623.001]
  • [Cites] AIDS Educ Prev. 2009 Oct;21(5):430-46 [19842827.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 Jan;53(1):111-6 [19779357.001]
  • [Cites] J Infect Dis. 2010 Jun 1;201(11):1677-85 [20415595.001]
  • [Cites] Oncology (Williston Park). 2010 Apr 15;24(4):364-9 [20464850.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Sex Transm Dis. 2003 Aug;30(8):639-44 [12897686.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Am J Med. 1997 May 5;102(5A):3-8 [9217656.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1386-8 [9358136.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] AIDS. 1998 Jul 9;12(10):1177-84 [9677167.001]
  • [Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]
  • [Cites] Obstet Gynecol. 2000 Dec;96(6):879-85 [11084171.001]
  • (PMID = 21151900.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2997781
  •  go-up   go-down


23. Carroll-Anzinger D, Kumar A, Adarichev V, Kashanchi F, Al-Harthi L: Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway. J Virol; 2007 Jun;81(11):5864-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocyte dysregulation correlates with the severity and the rate of human immunodeficiency virus (HIV)-associated dementia (HAD) progression, highlighting a pivotal role for astrocytes in HIV neuropathogenesis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Glia. 1999 Nov;28(2):85-96 [10533053.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3842-52 [16648479.001]
  • [Cites] Virology. 1999 Nov 25;264(2):370-84 [10562499.001]
  • [Cites] J Virol. 2000 Mar;74(6):2594-602 [10684273.001]
  • [Cites] Bioessays. 2000 Aug;22(8):708-16 [10918301.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [11080812.001]
  • [Cites] J Virol. 2001 Mar;75(6):2675-83 [11222691.001]
  • [Cites] Eur J Immunol. 2001 Jan;31(1):285-93 [11265645.001]
  • [Cites] J Neurochem. 2001 Jun;77(6):1601-10 [11413243.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):306-12 [11414473.001]
  • [Cites] J Virol. 2001 Sep;75(17):7925-33 [11483737.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1133-42 [11522183.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33899-905 [11438532.001]
  • [Cites] J Virol. 2002 May;76(9):4526-35 [11932418.001]
  • [Cites] Blood. 2002 May 15;99(10):3692-701 [11986225.001]
  • [Cites] J Virol. 2002 Aug;76(16):8374-82 [12134041.001]
  • [Cites] J Virol. 2002 Nov;76(21):11159-65 [12368361.001]
  • [Cites] J Infect Dis. 2002 Dec 1;186 Suppl 2:S193-8 [12424697.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4440-8 [12475984.001]
  • [Cites] J Gen Virol. 2006 Jun;87(Pt 6):1613-23 [16690926.001]
  • [Cites] Curr Pharm Des. 2006;12(16):1975-93 [16787242.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4361-9 [16532032.001]
  • [Cites] Brain Pathol. 2003 Jan;13(1):84-94 [12580548.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):144-54 [12744468.001]
  • [Cites] J Neurovirol. 2004;10 Suppl 1:25-32 [14982736.001]
  • [Cites] J Virol. 2004 Apr;78(8):4120-33 [15047828.001]
  • [Cites] Curr HIV Res. 2003 Oct;1(4):463-73 [15049431.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4847-55 [15077166.001]
  • [Cites] EMBO J. 2004 Oct 1;23(19):3815-24 [15372075.001]
  • [Cites] AIDS Res. 1984-1985;1(6):447-54 [6100783.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089-93 [3018755.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 May;84(10):3526-30 [3472222.001]
  • [Cites] J Neuropathol Exp Neurol. 1987 Jul;46(4):474-84 [3648096.001]
  • [Cites] J Virol. 1991 Nov;65(11):6094-100 [1920627.001]
  • [Cites] J Clin Microbiol. 1992 Jan;30(1):36-40 [1734067.001]
  • [Cites] J Virol. 1994 Jan;68(1):93-102 [8254781.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1207-11 [7848678.001]
  • [Cites] J Virol. 1995 Apr;69(4):2159-67 [7884864.001]
  • [Cites] J Biol Chem. 1995 Nov 17;270(46):27920-31 [7499267.001]
  • [Cites] J Neurovirol. 1996 Jun;2(3):158-66 [8799208.001]
  • [Cites] J Virol. 1996 Nov;70(11):7992-8002 [8892923.001]
  • [Cites] J Virol. 1999 Jan;73(1):352-61 [9847339.001]
  • [Cites] J Neurovirol. 1999 Apr;5(2):115-24 [10321975.001]
  • [Cites] J Virol. 1999 Oct;73(10):8279-89 [10482578.001]
  • [Cites] Biochim Biophys Acta. 1999 Oct 29;1424(2-3):M23-37 [10528152.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):395-401 [15544459.001]
  • [Cites] Glia. 2005 Feb;49(3):360-74 [15538753.001]
  • [Cites] Curr HIV Res. 2005 Jan;3(1):61-71 [15638724.001]
  • [Cites] Virology. 2005 Jul 5;337(2):242-52 [15916790.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Sep;5(5):529-60 [16178777.001]
  • [Cites] J Virol. 2005 Oct;79(20):12763-72 [16188979.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8869-77 [16204058.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1370-5 [16251967.001]
  • [Cites] Gene. 2005 Dec 19;363:67-76 [16236470.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):7981-8 [16339534.001]
  • [Cites] J Virol. 2006 Jan;80(1):541-4 [16352578.001]
  • [Cites] Eur J Immunol. 2006 Feb;36(2):278-86 [16385629.001]
  • [Cites] Curr Top Microbiol Immunol. 2005;290:225-52 [16480045.001]
  • [Cites] Virology. 2006 Apr 25;348(1):141-55 [16445956.001]
  • [Cites] Cancer Treat Rev. 2006 May;32(3):157-65 [16516391.001]
  • [Cites] Acta Neuropathol. 1999 Nov;98(5):481-7 [10541871.001]
  • (PMID = 17392368.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Transcription Factor 7-Like 2 Protein; 0 / Wnt Proteins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC1900315
  •  go-up   go-down


24. Kumar A, Ahuja A, Ali J, Baboota S: Conundrum and therapeutic potential of curcumin in drug delivery. Crit Rev Ther Drug Carrier Syst; 2010;27(4):279-312
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the past few decades, a number of studies have been done on curcumin showing its potential role in treating inflammatory disorders, cardiovascular disease, cancer, AIDS, and neurological disorders.
  • However, the main drawback associated with curcumin is its poor aqueous solubility and stability in gastrointestinal fluids, which leads to poor bioavailability.
  • These attempts have revealed promising results for enhanced bioavailability and targeting to disease such as cancer, but more extensive research on tissue-targeting and stability-related issues is needed.
  • Tissue targeting and enhanced bioavailability of curcumin using novel drug-delivery methods with minimum side effects will in the near future bring this promising natural product to the forefront of therapy for the treatment of human diseases such as cancer and cardiovascular ailments.

  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20932240.001).
  • [ISSN] 2162-660X
  • [Journal-full-title] Critical reviews in therapeutic drug carrier systems
  • [ISO-abbreviation] Crit Rev Ther Drug Carrier Syst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dosage Forms; IT942ZTH98 / Curcumin
  •  go-up   go-down


25. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, Minarovits J: The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis; 2009;1(2):e2009012
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.
  • Epstein-Barr virus (EBV), a human gammaherpesvirus, is associated with a series of malignant tumors.
  • These include lymphomas (Burkitt's lymphoma, Hodgkin's disease, T/NK-cell lymphoma, post-transplant lymphoproliferative disease, AIDS-associated lymphoma, X-linked lymphoproliferative syndrome), carcinomas (nasopharyngeal carcinoma, gastric carcinoma, carcinomas of major salivary glands, thymic carcinoma, mammary carcinoma) and a sarcoma (leiomyosarcoma).
  • Based on the cell type specific epigenetic marks associated with latent EBV genomes one can distinguish between viral epigenotypes that differ in transcriptional activity in spite of having an identical (or nearly identical) DNA sequence.
  • EBNA3C (EBNA6) seems to be associated both with histone acetylases and deacetylases, although in separate complexes.
  • LMP1, a transmembrane protein involved in malignant transformation, can affect both alternative systems of epigenetic memory, DNA methylation and the Polycomb-trithorax group of protein complexes.
  • These interactions may result in epigenetic dysregulation and subsequent cellular dysfunctions that may manifest in or contribute to the development of pathological changes (e.g. initiation and progression of malignant neoplasms, autoimmune phenomena, immunodeficiency).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1992 May 11;20(9):2287-91 [1594447.001]
  • [Cites] J Gen Virol. 1992 Jul;73 ( Pt 7):1687-92 [1321209.001]
  • [Cites] Virology. 1994 May 1;200(2):661-7 [8178450.001]
  • [Cites] J Virol. 1994 Sep;68(9):5375-83 [8057421.001]
  • [Cites] Science. 1995 Apr 28;268(5210):560-3 [7725102.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):6150-9 [7565767.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3129-36 [8874213.001]
  • [Cites] J Virol. 1997 Mar;71(3):1938-45 [9032325.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):187-91 [9620779.001]
  • [Cites] J Mol Biol. 2005 Jul 22;350(4):631-40 [15967459.001]
  • [Cites] Am J Hematol. 2006 Jan;81(1):5-11 [16369970.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 [16606841.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2995-3002 [16707594.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • [Cites] J Bacteriol. 2006 Dec;188(23):8160-8 [16997949.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5722-35 [10891508.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Virol. 2001 Mar;75(6):2584-96 [11222681.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):469-76 [11669609.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):442-3 [17392803.001]
  • [Cites] J Virol. 2007 Jun;81(12):6389-401 [17409162.001]
  • [Cites] EMBO J. 2007 Oct 3;26(19):4252-62 [17853891.001]
  • [Cites] J Virol. 2007 Dec;81(23):13242-7 [17898065.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):705-9 [18258198.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] J Virol. 2002 May;76(10):4699-708 [11967287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):4035-40 [12427740.001]
  • [Cites] J Virol. 2003 Apr;77(7):4261-72 [12634383.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1443-50 [12771413.001]
  • [Cites] J Virol. 2003 Jul;77(14):8166-72 [12829856.001]
  • [Cites] Virus Genes. 2003 Aug;27(1):57-66 [12913358.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19278-83 [17159145.001]
  • [Cites] J Gen Virol. 2008 Jun;89(Pt 6):1364-70 [18474551.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] J Virol. 2009 Apr;83(7):2930-40 [19129441.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Virol. 2009 Jul;83(14):7109-16 [19403674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):430-5 [10618435.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2343-9 [10713158.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):131-7 [11801549.001]
  • [Cites] Adv Cancer Res. 2003;89:133-56 [14587872.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1326-31 [14961078.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Trends Microbiol. 2004 Nov;12(11):495-9 [15488390.001]
  • [Cites] J Virol. 2004 Nov;78(22):12308-19 [15507618.001]
  • [Cites] Science. 1980 Nov 7;210(4470):604-10 [6254144.001]
  • [Cites] J Virol. 1983 May;46(2):446-53 [6302313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 [6328526.001]
  • [Cites] J Virol. 1998 Sep;72(9):7075-83 [9696800.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):46-56 [9858530.001]
  • [Cites] Science. 1999 May 7;284(5416):967-70 [10320378.001]
  • [Cites] Gene. 1999 Aug 5;236(1):87-95 [10433969.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] J Virol. 2004 Dec;78(24):14062-5 [15564516.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):542-52 [15706033.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):286-95 [15959556.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):344-53 [15959560.001]
  • [Cites] J Gen Virol. 1985 Sep;66 ( Pt 9):1931-40 [2993484.001]
  • [Cites] Nature. 1986 May 15-21;321(6067):209-13 [2423876.001]
  • [Cites] Cell. 1986 Dec 26;47(6):883-9 [3022942.001]
  • [Cites] Adv Cancer Res. 1988;50:95-158 [2837072.001]
  • [Cites] Cell. 1988 Jul 1;54(1):127-35 [2838178.001]
  • [Cites] Cell. 1988 Nov 4;55(3):427-33 [2846181.001]
  • [Cites] J Mol Biol. 1988 Oct 20;203(4):971-83 [3210246.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(17):6498-502 [2549539.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):179-87 [1968655.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):285-97 [1968665.001]
  • [Cites] J Virol. 1990 Nov;64(11):5295-300 [2170673.001]
  • [Cites] EMBO J. 1991 Jan;10(1):143-51 [1846596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3942-6 [1850841.001]
  • [Cites] J Virol. 1992 Jan;66(1):62-9 [1370095.001]
  • [Cites] J Gen Virol. 1991 Dec;72 ( Pt 12):3025-33 [1662694.001]
  • (PMID = 21416002.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033174
  •  go-up   go-down


26. Majerciak V, Kruhlak M, Dagur PK, McCoy JP Jr, Zheng ZM: Caspase-7 cleavage of Kaposi sarcoma-associated herpesvirus ORF57 confers a cellular function against viral lytic gene expression. J Biol Chem; 2010 Apr 9;285(15):11297-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caspase-7 cleavage of Kaposi sarcoma-associated herpesvirus ORF57 confers a cellular function against viral lytic gene expression.
  • Kaposi sarcoma-associated herpesvirus (KSHV) ORF57 is a viral early protein essential for KSHV multiplication.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1516-28 [19273144.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):837-41 [12213577.001]
  • [Cites] J Virol. 2003 Apr;77(7):4205-20 [12634378.001]
  • [Cites] J Virol. 2003 Apr;77(7):4221-30 [12634379.001]
  • [Cites] Immunol Rev. 2003 Jun;193:10-21 [12752666.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):6065-72 [12794135.001]
  • [Cites] Genes Dev. 2003 Jun 15;17(12):1475-86 [12783855.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3635-41 [12824383.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12461-6 [15314233.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] Cell. 1996 Oct 18;87(2):171 [8861900.001]
  • [Cites] J Cell Biol. 1998 Jan 12;140(1):171-82 [9425165.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9357-60 [9545256.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):897-907 [15520809.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1989-96 [15483679.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):857-60 [15569692.001]
  • [Cites] Blood. 2005 May 15;105(10):4028-34 [15687238.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35337-45 [16123041.001]
  • [Cites] J Virol. 2005 Nov;79(22):14207-21 [16254356.001]
  • [Cites] Science. 2006 Feb 10;311(5762):847-51 [16469926.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):11887-93 [16520380.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14076-84 [16567804.001]
  • [Cites] J Virol. 2006 Jun;80(11):5251-60 [16699005.001]
  • [Cites] Science. 2006 Jun 30;312(5782):1874 [16809511.001]
  • [Cites] Circ Res. 2006 Aug 18;99(4):415-23 [16857965.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):763-5 [16921264.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28365-78 [16829516.001]
  • [Cites] J Virol. 2006 Dec;80(24):11968-81 [17020939.001]
  • [Cites] Cell Death Differ. 2007 Jan;14(1):66-72 [17082814.001]
  • [Cites] J Virol. 2007 Feb;81(3):1062-71 [17108026.001]
  • [Cites] BMC Bioinformatics. 2006;7 Suppl 5:S14 [17254298.001]
  • [Cites] Cell Death Differ. 2007 Jul;14(7):1237-43 [17431418.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):30150-60 [17646170.001]
  • [Cites] J Virol. 2007 Nov;81(21):11850-60 [17699575.001]
  • [Cites] Proteomics. 2007 Dec;7(24):4457-67 [18072206.001]
  • [Cites] Blood. 2008 Jan 1;111(1):320-7 [17890449.001]
  • [Cites] Cell Death Differ. 2008 Feb;15(2):322-31 [17975551.001]
  • [Cites] J Virol. 2008 Mar;82(6):2792-801 [18184716.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):18135-46 [18450750.001]
  • [Cites] J Virol. 2002 Jan;76(2):802-16 [11752170.001]
  • (PMID = 20159985.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / RNA, Small Interfering; 0 / RNA, Viral; 0 / Viral Proteins; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  • [Other-IDs] NLM/ PMC2857008
  •  go-up   go-down


27. Sherman DW, Ye XY, McSherry C, Parkas V, Calabrese M, Gatto M: Quality of life of patients with advanced cancer and acquired immune deficiency syndrome and their family caregivers. J Palliat Med; 2006 Aug;9(4):948-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life of patients with advanced cancer and acquired immune deficiency syndrome and their family caregivers.
  • (1) establish the reliability of multidimensional quality of life instruments based on patients with acquired immune deficiency syndrome (AIDS) and patients with cancer and caregivers;.
  • (2) identify differences in quality of life between patients with advanced AIDS and cancer, and their family caregivers with consideration of mortality, attrition, and compliance rates; and (3) examine differences in demographic variables and their potential confounding effect when measuring quality of life.
  • METHODS: The sample included 101 patients with advanced illness (63 patients with advanced AIDS and 38 with advanced cancer) and 81 family caregivers (43 caregivers for patients with AIDS and 38 caregivers for patients with cancer).
  • RESULTS: Reliability of the MQOL and QLS were established for patients with AIDS and patients with cancer and caregivers.
  • Based on the MQOL, patients with advanced AIDS reported a lower total quality of life, and lower psychological quality of life, and a higher physical quality of life compared to patients with advanced cancer.
  • Based on the QLS, AIDS caregivers reported greater overall quality of life, greater psychological well-being, and greater spiritual well-be- ing than cancer caregivers.
  • There were no significant differences between AIDS and cancer caregivers with respect to physical or social well-being.
  • Fourteen of 63 (22%) patients with AIDS patients died, while 19 of 38 (50%) patients with advanced cancer died after enrollment.
  • Forty-six of 63 (73%) patients with advanced AIDS withdrew for various reasons other than death at some point during the 12 month time frame of the study, while 15 of 38 (39%) patients with advanced cancer withdrew.
  • There were significant differences on all demographic variables for patients with advanced cancer and AIDS.
  • Only religious affiliation was significantly related to quality of life for patients with AIDS, while gender was the only variable associated with quality of life for patients with cancer.
  • Only the relationship between patients and caregivers and marital status were significantly associated with quality of life for cancer caregivers.


28. Galea S, Rudenstine S: Challenges in understanding disparities in drug use and its consequences. J Urban Health; 2005 Jun;82(2 Suppl 3):iii5-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For example, Blacks have higher HIV incidence and AIDS-related mortality than do Whites.
  • (b) racial/ethnic differences in use of drugs are not always associated with comparable differences in the consequences of drug use; and (c) the consequences of drug use are associated with drug use itself and other social/economic circumstances.

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Psychoactive Drugs. 1994 Jul-Sep;26(3):265-75 [7844656.001]
  • [Cites] Can J Public Health. 2002 Jul-Aug;93(4):303-7 [12154535.001]
  • [Cites] N Engl J Med. 1995 Sep 21;333(12):751-6 [7643881.001]
  • [Cites] J Epidemiol Community Health. 1995 Dec;49 Suppl 2:S72-7 [8594138.001]
  • [Cites] J Stud Alcohol. 1996 Sep;57(5):521-30 [8858549.001]
  • [Cites] Drug Alcohol Depend. 1997 Jan 10;44(1):11-29 [9031816.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):253-61 [9495226.001]
  • [Cites] J Adolesc Health. 1998 Sep;23(3):167-80 [9730360.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Mar-Apr;111(2):109-18 [10220805.001]
  • [Cites] Drug Alcohol Depend. 2002 Sep 1;68(1):65-85 [12167553.001]
  • [Cites] J Stud Alcohol. 2002 Sep;63(5):609-19 [12380858.001]
  • [Cites] Public Health Rep. 2002;117 Suppl 1:S15-29 [12435824.001]
  • [Cites] Public Health Rep. 2002;117 Suppl 1:S51-9 [12435827.001]
  • [Cites] Public Health Rep. 2002;117 Suppl 1:S67-75 [12435829.001]
  • [Cites] Public Health Rep. 2002;117 Suppl 1:S118-25 [12435835.001]
  • [Cites] Ann Epidemiol. 2003 Apr;13(4):294-302 [12684197.001]
  • [Cites] Addiction. 2003 May;98(5):673-84 [12751985.001]
  • [Cites] Ethn Dis. 2003 Fall;13(4):521-7 [14632272.001]
  • [Cites] Epidemiol Rev. 2004;26:36-52 [15234946.001]
  • [Cites] Am J Public Health. 2004 Aug;94(8):1386-92 [15284048.001]
  • [Cites] N Engl J Med. 2004 Sep 9;351(11):1137-42 [15356313.001]
  • [Cites] Ann N Y Acad Sci. 1981;362:231-8 [6942709.001]
  • [Cites] CMAJ. 1986 Jan 15;134(2):127-32 [3484656.001]
  • [Cites] Addict Behav. 1988;13(2):191-5 [3369329.001]
  • [Cites] Public Health Rep. 1988 Jul-Aug;103(4):387-93 [3136497.001]
  • [Cites] Am J Public Health. 1991 Mar;81(3):372-7 [1994746.001]
  • [Cites] Soc Sci Med. 1991;33(12):1355-64 [1776049.001]
  • [Cites] J Natl Cancer Inst. 1992 Apr 15;84(8):619-22 [1556772.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 17;85(6):465-73 [8445674.001]
  • [Cites] Ann Epidemiol. 1999 May;9(4):236-44 [10332929.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1358-63 [10755415.001]
  • [Cites] Addict Behav. 2000 May-Jun;25(3):361-71 [10890290.001]
  • [Cites] Addict Behav. 2000 May-Jun;25(3):399-414 [10890293.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):277-83 [11181774.001]
  • [Cites] J Health Soc Behav. 2001 Jun;42(2):151-65 [11467250.001]
  • [Cites] Am J Public Health. 2001 Sep;91(9):1424-30 [11527775.001]
  • [Cites] Am J Public Health. 2001 Nov;91(11):1847-50 [11684614.001]
  • [Cites] Am J Psychiatry. 2001 Dec;158(12):2027-32 [11729020.001]
  • [Cites] Subst Use Misuse. 2001 Dec;36(13):1901-22 [11795584.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Jan 25;51(3):49-53 [11843259.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):95-104 [12048369.001]
  • [Cites] Recent Dev Alcohol. 1995;12:369-86 [7624553.001]
  • (PMID = 15933331.001).
  • [ISSN] 1099-3460
  • [Journal-full-title] Journal of urban health : bulletin of the New York Academy of Medicine
  • [ISO-abbreviation] J Urban Health
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / DA 013146-S1; United States / NIDA NIH HHS / DA / DA 017642; United States / NIDA NIH HHS / DA / DA 018061
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  • [Other-IDs] NLM/ PMC3455901
  •  go-up   go-down


29. Thammavongsa V, Schaefer M, Filzen T, Collins KL, Carrington M, Bangia N, Raghavan M: Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503. Immunogenetics; 2009 Dec;61(11-12):703-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Residue 116 of major histocompatibility complex (MHC) class I heavy chains is an important determinant of assembly, that can influence rates of ER-Golgi trafficking, binding to the transporter associated with antigen processing (TAP), tapasin dependence of assembly, and the efficiency and specificity of peptide binding.
  • Here, we investigated assembly and peptide-binding differences between HLA-B*3501(S116) and HLA-B*3503(F116), two alleles differing only at position 116 of the MHC class I heavy chain, that are associated respectively with normal or rapid AIDS progression.
  • These findings suggest that compared to HLA-B*3501, a reduced intracellular peptide repertoire for HLA-B*3503 could contribute to its slower intracellular trafficking and stronger association with rapid AIDS progression.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):755-9 [10597191.001]
  • [Cites] Immunity. 2009 Apr 17;30(4):611 [19382300.001]
  • [Cites] Eur J Immunol. 2000 Oct;30(10):3021-8 [11069086.001]
  • [Cites] N Engl J Med. 2001 May 31;344(22):1668-75 [11386265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7241-6 [11416206.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1507-14 [11466371.001]
  • [Cites] J Immunol. 2001 Aug 15;167(4):2097-105 [11489993.001]
  • [Cites] Trends Mol Med. 2001 Sep;7(9):379-81 [11530315.001]
  • [Cites] Immunity. 2002 Apr;16(4):509-20 [11970875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5931-6 [11983893.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Nov 20;18(17):1319-25 [12487820.001]
  • [Cites] Annu Rev Med. 2003;54:535-51 [12525683.001]
  • [Cites] J Virol. 2003 Mar;77(5):3041-9 [12584329.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5287-95 [14607930.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):13-24 [15226359.001]
  • [Cites] Eur J Immunol. 2004 Sep;34(9):2510-9 [15307183.001]
  • [Cites] Mol Cell. 2004 Sep 24;15(6):913-23 [15383281.001]
  • [Cites] Cell. 1978 May;14(1):9-20 [667938.001]
  • [Cites] Nature. 1987 Oct 8-14;329(6139):506-12 [3309677.001]
  • [Cites] Int Immunol. 1990;2(2):113-25 [2088481.001]
  • [Cites] J Mol Biol. 1991 May 20;219(2):277-319 [2038058.001]
  • [Cites] J Acquir Immune Defic Syndr. 1992;5(1):37-45 [1738086.001]
  • [Cites] Immunogenetics. 1993;38(2):161-2 [8482580.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6 [7690960.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12716-20 [7809108.001]
  • [Cites] Eur J Immunol. 1995 Jan;25(1):102-10 [7531142.001]
  • [Cites] Immunogenetics. 1996;43(1-2):105-7 [8537112.001]
  • [Cites] Nat Med. 1996 Apr;2(4):405-11 [8597949.001]
  • [Cites] J Immunol. 1996 May 1;156(9):3196-206 [8617941.001]
  • [Cites] Immunity. 1996 Mar;4(3):203-13 [8624811.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):8976-81 [9256420.001]
  • [Cites] J Virol. 1997 Oct;71(10):7429-35 [9311821.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):397-401 [9450757.001]
  • [Cites] Immunity. 1998 Feb;8(2):221-31 [9492003.001]
  • [Cites] Immunity. 1999 Sep;11(3):281-8 [10514006.001]
  • [Cites] J Cell Biol. 2004 Dec 6;167(5):903-13 [15569716.001]
  • [Cites] Nature. 2004 Dec 9;432(7018):769-75 [15592417.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):23900-9 [15849183.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):138-47 [16385505.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3150-61 [16920953.001]
  • [Cites] PLoS Med. 2006 Oct;3(10):e403 [17076553.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7646-52 [18025210.001]
  • [Cites] Immunology. 2008 May;124(1):112-20 [18194274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 [10694578.001]
  • (PMID = 19838694.001).
  • [ISSN] 1432-1211
  • [Journal-full-title] Immunogenetics
  • [ISO-abbreviation] Immunogenetics
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI044115; United States / NIAID NIH HHS / AI / AI44155; United States / NIAID NIH HHS / AI / R01 AI044115-01; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CA / HHSN261200800001E
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Sub-Family B Member 2; 0 / ATP-Binding Cassette Transporters; 0 / HLA-B Antigens; 0 / HLA-B*35:01 antigen; 0 / HLA-B35 Antigen; 0 / Membrane Transport Proteins; 0 / Peptides; 0 / TAP1 protein, human; 0 / tapasin
  • [Other-IDs] NLM/ NIHMS155775; NLM/ PMC2971690
  •  go-up   go-down


30. Insinga RP, Dasbach EJ, Elbasha EH: Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics; 2005;23(11):1107-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
  • Comprehensive estimates of the annual economic burden associated with the prevention and treatment of anogenital HPV-related disease in the US population are currently unavailable.
  • The purpose of this paper is to (i) outline an analytic framework from which to estimate the annual economic burden of preventing and treating anogenital HPV-related disease in the US;.
  • Among eight US studies identified that describe the annual economic burden pertaining to one or more aspects of anogenital HPV-related disease, three met the review eligibility criteria (published between 1990 and 2004, examined multiple facets of annual anogenital HPV-related economic burden, and clearly articulated the data and methods used in the estimation process).
  • Estimates of the annual direct medical costs associated with cervical cancer were comparable across studies (range 300-400 million US dollars).
  • In contrast, there was a wide range across studies for estimates of the annual direct medical costs associated with cervical intraepithelial neoplasia (range 700 million US dollars-2.3 billion US dollars).
  • Only one study reported direct medical costs for anogenital warts (200 million US dollars) and routine cervical cancer screening (2.3 billion US dollars).
  • No studies examined direct medical costs attributable to HPV-related anal, penile, vaginal or vulvar cancers, or the work and productivity losses resulting from time spent receiving medical care, morbidity or mortality.
  • Current economic burden estimates would suggest annual direct medical costs associated with the prevention and treatment of anogenital warts and cervical HPV-related disease of at least 4 billion US dollars.
  • This figure would likely rise to at least 5 billion US dollars per year if direct medical costs associated with other disease entities caused by the sexual transmission of HPV were included, with further additions to the economic burden totalling in the billions of dollars if work and productivity losses were incorporated, a research priority for future studies.


31. Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA: HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood; 2010 Feb 18;115(7):1354-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Delivery of virion-associated Vpr via defective HIV-1 particles induced analogous biologic effects in noninfected target cells, suggesting that Vpr may act similarly beyond infected cells.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1986 Aug;59(2):284-91 [3016298.001]
  • [Cites] J Virol. 1995 Oct;69(10):6304-13 [7666531.001]
  • [Cites] J Virol. 1995 Nov;69(11):6705-11 [7474080.001]
  • [Cites] J Virol. 1995 Nov;69(11):6859-64 [7474100.001]
  • [Cites] J Virol. 1995 Nov;69(11):6873-9 [7474102.001]
  • [Cites] J Virol. 1995 Nov;69(11):7032-44 [7474123.001]
  • [Cites] J Virol. 1996 Apr;70(4):2516-24 [8642681.001]
  • [Cites] J Virol. 1997 Jun;71(6):4331-8 [9151821.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1103-11 [9529326.001]
  • [Cites] J Virol. 1998 Jul;72(7):5441-8 [9620999.001]
  • [Cites] Science. 1998 Jul 10;281(5374):266-9 [9657723.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):9083-91 [10085158.001]
  • [Cites] J Virol. 1999 May;73(5):4101-9 [10196306.001]
  • [Cites] Immunity. 1999 Jun;10(6):661-71 [10403641.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9152-9 [15604286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2886-91 [15699323.001]
  • [Cites] Annu Rev Immunol. 2005;23:225-74 [15771571.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1093-7 [15793563.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1148-52 [15793562.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1711-7 [15886320.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):928-37 [16116470.001]
  • [Cites] Nature. 2005 Aug 25;436(7054):1186-90 [15995699.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3366-9 [16002429.001]
  • [Cites] J Virol. 2006 Nov;80(21):10407-18 [16956949.001]
  • [Cites] J Gen Virol. 2007 Jan;88(Pt 1):242-50 [17170457.001]
  • [Cites] Cell Cycle. 2007 Jan 15;6(2):182-8 [17314515.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4130-5 [17360488.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 Mar;23(3):391-7 [17411372.001]
  • [Cites] Virol J. 2007;4:57 [17559673.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11778-83 [17609381.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1207-14 [17513617.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):27046-57 [17620334.001]
  • [Cites] J Virol. 2007 Oct;81(19):10822-30 [17626091.001]
  • [Cites] PLoS Pathog. 2007 Jul;3(7):e85 [17630831.001]
  • [Cites] Front Biosci. 2008;13:3448-56 [18508446.001]
  • [Cites] Cell Host Microbe. 2008 Jun 12;3(6):388-98 [18541215.001]
  • [Cites] J Virol. 2008 Jul;82(14):7189-200 [18417583.001]
  • [Cites] PLoS Pathog. 2008 Jul;4(7):e1000101 [18617991.001]
  • [Cites] J Exp Med. 2001 Nov 19;194(10):1407-19 [11714748.001]
  • [Cites] Nature. 2002 Oct 17;419(6908):734-8 [12384702.001]
  • [Cites] Virology. 2002 Oct 10;302(1):95-105 [12429519.001]
  • [Cites] AIDS. 2003 Mar 7;17(4):487-94 [12598768.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25879-86 [12738771.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28346-53 [12746459.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1389-96 [12714493.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] J Virol. 2003 Nov;77(21):11708-17 [14557656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15011-6 [14645713.001]
  • [Cites] J Virol. 2004 Mar;78(6):3170-7 [14990738.001]
  • [Cites] J Chromatogr. 1985 Jun 19;326:357-61 [3875623.001]
  • (PMID = 20008788.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] None / None / / 12381-4; Canada / Canadian Institutes of Health Research / / 12381-4; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / GPI-Linked Proteins; 0 / Immunologic Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / KLRK1 protein, human; 0 / Ligands; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Cell Surface; 0 / ULBP2 protein, human; 0 / vpr Gene Products, Human Immunodeficiency Virus; 0 / vpr protein, Human immunodeficiency virus 1; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ CAMS4124; NLM/ PMC3955183
  •  go-up   go-down


32. Reinhart TA, Qin S, Sui Y: Multiple roles for chemokines in the pathogenesis of SIV infection. Curr HIV Res; 2009 Jan;7(1):73-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The complex immunobiology of chemokines, coupled with the use of subsets of chemokine receptors as HIV-1 and SIV entry co-receptors, suggests that these immunomodulators could play important roles in the pathogenesis associated with infection by HIV-1 or SIV.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1997 Apr 15;158(8):3721-9 [9103436.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4005-10 [9108095.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):238 [9230431.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):296-300 [9230441.001]
  • [Cites] J Exp Med. 1997 Aug 4;186(3):405-11 [9236192.001]
  • [Cites] J Virol. 1997 Sep;71(9):6296-304 [9261346.001]
  • [Cites] J Virol. 1997 Sep;71(9):6509-16 [9261370.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1160-2 [9334732.001]
  • [Cites] Nature. 1997 Oct 30;389(6654):981-5 [9353123.001]
  • [Cites] J Infect Dis. 1997 Nov;176(5):1198-208 [9359719.001]
  • [Cites] Science. 1997 Nov 21;278(5342):1462-4 [9367958.001]
  • [Cites] J Virol. 1997 Dec;71(12):8999-9007 [9371556.001]
  • [Cites] J Exp Med. 1997 Dec 1;186(11):1865-72 [9382885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14742-7 [9405683.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):129-34 [9419219.001]
  • [Cites] Curr Opin Pulm Med. 2000 May;6(3):240-5 [10782710.001]
  • [Cites] Nat Med. 2000 May;6(5):543-8 [10802710.001]
  • [Cites] Annu Rev Immunol. 2000;18:767-811 [10837075.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1674-80 [10961862.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2206-14 [10979967.001]
  • [Cites] Immunol Rev. 2000 Oct;177:112-26 [11138769.001]
  • [Cites] J Vet Med Sci. 2000 Dec;62(12):1311-2 [11193348.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1920-4 [11264152.001]
  • [Cites] Nat Immunol. 2001 Feb;2(2):102-7 [11175801.001]
  • [Cites] J Virol. 2001 May;75(9):4448-52 [11287599.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):2986-91 [11110785.001]
  • [Cites] J Med Primatol. 2001 Feb;30(1):1-13 [11396858.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):29839-45 [11390394.001]
  • [Cites] Blood. 2001 Aug 15;98(4):925-33 [11493434.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3064-73 [11544290.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3554-61 [11739156.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2859-68 [11929776.001]
  • [Cites] AIDS. 2002 Mar 29;16(5):683-92 [11964524.001]
  • [Cites] Blood. 2002 May 1;99(9):3119-28 [11964273.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4301-7 [11970971.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14 [11994741.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):271-6 [11997671.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Jun 10;18(9):627-39 [12079558.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):183-91 [12101279.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1160-7 [12149192.001]
  • [Cites] Allergy. 2002 Nov;57(11):972-82 [12358993.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Feb;47(2):509-17 [12543651.001]
  • [Cites] Nat Med. 2003 Feb;9(2):191-7 [12539042.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1684-91 [12406887.001]
  • [Cites] J Infect Dis. 2003 Feb 15;187(4):576-88 [12599074.001]
  • [Cites] Immunology. 2003 Apr;108(4):523-30 [12667214.001]
  • [Cites] Virology. 2003 Mar 1;307(1):122-34 [12667820.001]
  • [Cites] Blood. 2003 Aug 1;102(3):789-94 [12689946.001]
  • [Cites] Eur J Immunol. 2003 Aug;33(8):2241-50 [12884299.001]
  • [Cites] J Leukoc Biol. 2003 Sep;74(3):448-55 [12949249.001]
  • [Cites] J Med Primatol. 2003 Aug;32(4-5):229-39 [14498983.001]
  • [Cites] J Med Primatol. 2003 Aug;32(4-5):247-64 [14498985.001]
  • [Cites] Nat Neurosci. 2003 Oct;6(10):1064-71 [14502291.001]
  • [Cites] Immunol Rev. 2006 Aug;212:8-27 [16903903.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3808-17 [16902147.001]
  • [Cites] J Biol Chem. 2006 Dec 1;281(48):36652-61 [17023422.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1170-80 [17146291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19182-7 [17148615.001]
  • [Cites] Curr HIV/AIDS Rep. 2007 Feb;4(1):10-5 [17338855.001]
  • [Cites] Annu Rev Immunol. 2007;25:787-820 [17291188.001]
  • [Cites] J Virol. 2007 May;81(9):4445-56 [17314162.001]
  • [Cites] Thromb Haemost. 2007 May;97(5):755-62 [17479186.001]
  • [Cites] J Virol. 2007 Jun;81(12):6175-86 [17428863.001]
  • [Cites] J Immunol. 2007 Jun 15;178(12):7658-66 [17548602.001]
  • [Cites] Blood. 2007 Jul 1;110(1):37-44 [17363734.001]
  • [Cites] J Allergy Clin Immunol. 2007 Aug;120(2):247-54 [17666214.001]
  • [Cites] PLoS One. 2007;2(8):e726 [17684570.001]
  • [Cites] Drugs. 2007;67(15):2277-88; discussion 2289-90 [17927288.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1551-62 [14623909.001]
  • [Cites] J Pathol. 2003 Dec;201(4):616-28 [14648666.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1526-9 [14976262.001]
  • [Cites] Semin Immunol. 2003 Oct;15(5):271-6 [15001176.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1557-66 [15111302.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23357-63 [15039444.001]
  • [Cites] J Virol. 2004 Jun;78(12):6399-408 [15163733.001]
  • [Cites] Blood. 2004 Aug 1;104(3):619-25 [15059845.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):617-29 [15286728.001]
  • [Cites] J Leukoc Biol. 2004 Sep;76(3):701-8 [15178708.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):749-59 [15365096.001]
  • [Cites] Science. 2004 Oct 15;306(5695):485-7 [15486300.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7579-87 [15492285.001]
  • [Cites] J Immunol. 1986 Apr 1;136(7):2348-57 [2419430.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):609-21 [1716047.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1273-80 [1750503.001]
  • [Cites] Vet Pathol. 1991 Nov;28(6):506-13 [1771740.001]
  • [Cites] J Pathol. 1992 Jun;167(2):241-7 [1378892.001]
  • [Cites] J Infect Dis. 1993 Oct;168(4):836-43 [8376830.001]
  • [Cites] Science. 1993 Dec 24;262(5142):2045-50 [7903479.001]
  • [Cites] Parasitol Res. 1993;79(8):624-8 [8295897.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6594-8 [7912830.001]
  • [Cites] J Virol. 1994 Oct;68(10):6535-46 [7916060.001]
  • [Cites] FEBS Lett. 1994 Oct 31;354(1):1-6 [7957888.001]
  • [Cites] AIDS. 1994 Dec;8(12):1727-8 [7888123.001]
  • [Cites] Nat Med. 1995 Sep;1(9):919-26 [7585218.001]
  • [Cites] Science. 1995 Dec 15;270(5243):1811-5 [8525373.001]
  • [Cites] J Biol Chem. 1996 Feb 2;271(5):2599-603 [8576227.001]
  • [Cites] Science. 1996 May 10;272(5263):872-7 [8629022.001]
  • [Cites] Virology. 1996 Jun 15;220(2):320-9 [8661383.001]
  • [Cites] Nature. 1996 Jun 20;381(6584):661-6 [8649511.001]
  • [Cites] Nature. 1996 Jun 20;381(6584):667-73 [8649512.001]
  • [Cites] Nat Med. 1996 Jul;2(7):767-75 [8673922.001]
  • [Cites] Cell. 1996 Jun 28;85(7):1135-48 [8674119.001]
  • [Cites] Cell. 1996 Jun 28;85(7):1149-58 [8674120.001]
  • [Cites] Science. 1996 Jun 28;272(5270):1955-8 [8658171.001]
  • [Cites] Cell. 1996 Aug 9;86(3):367-77 [8756719.001]
  • [Cites] Nature. 1996 Aug 22;382(6593):722-5 [8751444.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):829-33 [8752280.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):833-5 [8752281.001]
  • [Cites] Science. 1996 Sep 27;273(5283):1856-62 [8791590.001]
  • [Cites] Nature. 1996 Oct 31;383(6603):787-93 [8893001.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1459-67 [8909235.001]
  • [Cites] J Virol. 1997 Feb;71(2):1227-36 [8995646.001]
  • [Cites] J Virol. 1997 Mar;71(3):2522-7 [9032394.001]
  • [Cites] Cytokine. 1996 Nov;8(11):844-52 [9047081.001]
  • [Cites] J Virol. 1997 Apr;71(4):2705-14 [9060623.001]
  • [Cites] J Virol. 1997 May;71(5):3932-9 [9094670.001]
  • [Cites] Science. 1997 Apr 11;276(5310):276-9 [9092481.001]
  • [Cites] Lymphat Res Biol. 2007;5(2):91-103 [17935477.001]
  • [Cites] J Leukoc Biol. 2007 Dec;82(6):1375-81 [17709402.001]
  • [Cites] J Neuroimmune Pharmacol. 2006 Jun;1(2):138-51 [18040780.001]
  • [Cites] J Immunol. 2008 Jan 1;180(1):214-21 [18097022.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):16-26 [17971706.001]
  • [Cites] Int Rev Psychiatry. 2008 Feb;20(1):25-31 [18240060.001]
  • [Cites] Nat Immunol. 2008 Mar;9(3):301-9 [18264102.001]
  • [Cites] Respirology. 2008 Mar;13(2):181-90 [18339015.001]
  • [Cites] Annu Rev Immunol. 2008;26:741-66 [18173374.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5530-6 [18390737.001]
  • [Cites] Immunology. 2008 May;124(1):13-22 [18346152.001]
  • [Cites] ChemMedChem. 2008 Jun;3(6):861-72 [18442035.001]
  • [Cites] J Neurovirol. 2008 May;14(3):196-204 [18569454.001]
  • [Cites] Blood. 2008 Jul 15;112(2):256-63 [18347198.001]
  • [Cites] Genome Biol. 2006;7(12):243 [17201934.001]
  • [Cites] J Immunol. 1998 Mar 15;160(6):2872-80 [9510190.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3117-21 [9501225.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7222-7 [9516414.001]
  • [Cites] Science. 1998 Apr 17;280(5362):427-31 [9545219.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1215-24 [9547333.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6331-6 [9600965.001]
  • [Cites] FASEB J. 1998 Jun;12(9):705-13 [9619449.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18288-91 [9660793.001]
  • [Cites] J Virol. 1998 Aug;72(8):6421-9 [9658083.001]
  • [Cites] J Immunol. 1998 Nov 15;161(10):5111-5 [9820476.001]
  • [Cites] Virology. 1999 Mar 15;255(2):285-93 [10069954.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):32478-85 [10542293.001]
  • [Cites] Chem Immunol. 1999;72:42-56 [10550929.001]
  • [Cites] Science. 1999 Nov 12;286(5443):1353-7 [10558989.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2098-102 [10617422.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2487-95 [10679086.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Mar 1;16(4):381-92 [10716376.001]
  • [Cites] J Gen Virol. 1999 Mar;80 ( Pt 3):767-76 [10092018.001]
  • [Cites] Immunol Lett. 1999 Mar;66(1-3):37-46 [10203032.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):3840-50 [10201901.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4903-9 [10202035.001]
  • [Cites] Mol Membr Biol. 1999 Jan-Mar;16(1):49-55 [10332737.001]
  • [Cites] Virology. 1999 Jun 20;259(1):110-8 [10364494.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1237-45 [10415019.001]
  • [Cites] J Gen Virol. 1999 Jul;80 ( Pt 7):1569-74 [10423123.001]
  • [Cites] Nat Med. 1999 Sep;5(9):997-103 [10470075.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1899-905 [10477718.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):481-95 [15563311.001]
  • [Cites] J Neuroimmunol. 2004 Dec;157(1-2):66-70 [15579282.001]
  • [Cites] AIDS. 2005 Jan 28;19(2):107-17 [15668535.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):355-65 [15681820.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3143-7 [15749840.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4407-14 [15778406.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1082-91 [15761496.001]
  • [Cites] Immunity. 2005 Apr;22(4):493-505 [15845453.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1148-52 [15793562.001]
  • [Cites] Blood. 2005 May 15;105(10):3793-801 [15677562.001]
  • [Cites] J Leukoc Biol. 2005 Aug;78(2):442-52 [15923218.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5314-23 [16210637.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1324-32 [16210409.001]
  • [Cites] J Virol. 2005 Nov;79(21):13759-68 [16227295.001]
  • [Cites] J Virol. 2005 Nov;79(22):14355-70 [16254370.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7901-10 [16278415.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1293-4 [16273102.001]
  • [Cites] J Infect Dis. 2006 Mar 1;193(5):703-12 [16453267.001]
  • [Cites] AIDS. 2006 May 12;20(8):1095-107 [16691060.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):840-51 [16818738.001]
  • [Cites] Microbes Infect. 2006 Jun;8(7):1839-50 [16822691.001]
  • (PMID = 19149556.001).
  • [ISSN] 1873-4251
  • [Journal-full-title] Current HIV research
  • [ISO-abbreviation] Curr. HIV Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI060422; United States / NIAID NIH HHS / AI / AI060422
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chemokines
  • [Number-of-references] 182
  • [Other-IDs] NLM/ PMC3580803
  •  go-up   go-down


33. Falchi L, Capello D, Palumbo B, Rauco A, Emili R, Cianciulli M, Pace R, Capparella V, Liberati F, Liberati AM: A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy. Eur J Haematol; 2007 Nov;79(5):455-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of an Epstein-Barr virus (EBV)- and human immunodeficiency virus-serum negative patient suffering from repeatedly relapsing classical Hodgkin's Lymphoma (cHL) associated with a histological picture of plasma cell-hyaline vascular (PC-HV) form of Castleman's disease (CD).

  • Genetic Alliance. consumer health - Castleman's Disease.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2003 Jun 13;17(9):1409-10 [12799570.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):585-6 [15090823.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1939-41 [15223659.001]
  • [Cites] Blood. 1991 Jun 1;77(11):2413-8 [1710152.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):602-5 [8302342.001]
  • [Cites] Arch Pathol Lab Med. 1996 Jan;120(1):91-6 [8554455.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):569-71 [8652374.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] J Pathol. 1997 Sep;183(1):44-50 [9370946.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):482-5 [10086783.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):302-5 [15795923.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2627-32 [15998837.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):119-23 [16405432.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):882-8 [10843293.001]
  • [Cites] Head Neck. 2001 Feb;23(2):166-9 [11303634.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):790-1 [11577129.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3473-5 [11719390.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):1-5 [11815953.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):605-17 [12208876.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2786-8 [12842986.001]
  • (PMID = 17908180.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2121125
  •  go-up   go-down


34. Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, Parsa AT: CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci; 2010 Nov;17(11):1381-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.
  • Here we investigate whether the extent of local glioma-associated CD8+ T-cell infiltrate at initial presentation correlates with long-term survival in patients with glioblastoma multiforme (GBM).
  • Thus, CD8+ T-cell infiltrate is associated with prolonged survival.
  • Our data provide the impetus for more sophisticated studies to further elucidate prospectively the specific T-cell subtypes associated with long-term survival.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Brain Pathol. 2009 Oct;19(4):713-23 [19744042.001]
  • [Cites] Mol Cancer Ther. 2009 Oct;8(10):2773-9 [19825799.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4107-14 [11464277.001]
  • [Cites] Neurology. 2001 Oct 23;57(8):1486-8 [11673595.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):252-9 [11979441.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):144-52; discussion 152-3 [12823883.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8487-91 [14679014.001]
  • [Cites] Annu Rev Immunol. 2004;22:329-60 [15032581.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):310-9 [15086239.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Brain. 1971;94(1):117-24 [5552158.001]
  • [Cites] Acta Neuropathol. 1976;35(3):265-71 [181941.001]
  • [Cites] Ann Neurol. 1978 Sep;4(3):219-24 [718133.001]
  • [Cites] J Neurosurg. 1978 Dec;49(6):854-61 [731302.001]
  • [Cites] Tumori. 1979 Feb 28;65(1):119-25 [220763.001]
  • [Cites] J Neurosurg. 1984 Jun;60(6):1138-47 [6374063.001]
  • [Cites] Clin Neuropathol. 1984 Jul-Aug;3(4):143-7 [6478676.001]
  • [Cites] Surg Neurol. 1985 Mar;23(3):221-6 [2983448.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):738-43 [3338036.001]
  • [Cites] J Neurosurg. 1988 Mar;68(3):432-7 [2830373.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6926-32 [3052809.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1843-9 [2784352.001]
  • [Cites] Acta Neuropathol. 1989;78(2):189-93 [2750489.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):528-33 [2795172.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 [2593166.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):686-92 [8033048.001]
  • [Cites] AIDS. 1995 Apr;9(4):403-4 [7794551.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):43-7 [8569196.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1303-10 [8608507.001]
  • [Cites] J Infect. 1996 Nov;33(3):159-62 [8945703.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] Neurosurgery. 1999 Mar;44(3):636-42; discussion 642-3 [10069601.001]
  • [Cites] Front Biosci. 2005;10:2908-21 [15970545.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):12-26 [16443944.001]
  • [Cites] Neurosurg Focus. 2000;9(6):e8 [16817691.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):234-43 [16723631.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):261-79 [16775224.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7306-15 [17189402.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Cancer Immun. 2007;7:4 [17311363.001]
  • [Cites] Trends Mol Med. 2007 Mar;13(3):108-16 [17257897.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2158-67 [17404100.001]
  • [Cites] Cancer Immun. 2007;7:12 [17691714.001]
  • [Cites] Expert Opin Biol Ther. 2009 Aug;9(8):1087-98 [19591631.001]
  • (PMID = 20727764.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA132489; United States / NCI NIH HHS / CA / R01 CA052689; United States / NCI NIH HHS / CA / F32 CA132489-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Other-IDs] NLM/ NIHMS230845; NLM/ PMC3064460
  •  go-up   go-down


35. Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F, Hase S, Takebe Y, Pathak VK: Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine. J Virol; 2009 Sep;83(17):8502-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.
  • The high level of AZT resistance exhibited by CRF01_AE was primarily associated with the T400 residue in wild-type subtype AE CN subdomain.
  • These results show for the first time that CRF01_AE exhibits higher levels of AZT resistance in the presence of TAMs and that this resistance is primarily associated with T400.

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Resistance Testing .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1998 Jun;72(6):5093-8 [9573280.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9564-8 [7937806.001]
  • [Cites] AIDS. 2005 Jan 28;19(2):119-26 [15668536.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2093-8 [15684061.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Dec;21(12):1046-50 [16379608.001]
  • [Cites] Virology. 2006 Jul 20;351(1):1-6 [16777167.001]
  • [Cites] AIDS. 2006 Oct 24;20(16):W13-23 [17053344.001]
  • [Cites] Curr Opin Infect Dis. 2006 Dec;19(6):594-606 [17075337.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):523-9 [17031320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):317-22 [17179211.001]
  • [Cites] J Virol. 2007 Jul;81(13):6837-45 [17428874.001]
  • [Cites] J Virol. 2007 Aug;81(15):7852-9 [17507476.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):1370-4 [11684697.001]
  • [Cites] Biochemistry. 2002 Apr 16;41(15):4856-65 [11939780.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9515-20 [12093908.001]
  • [Cites] J Virol. 2007 Oct;81(19):10209-19 [17634242.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 Sep;23(9):1139-45 [17919110.001]
  • [Cites] Virology. 2007 Oct 25;367(2):288-97 [17604072.001]
  • [Cites] Retrovirology. 2007;4:67 [17892568.001]
  • [Cites] PLoS Med. 2007 Dec;4(12):e335 [18052601.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jan;52(1):157-63 [17967907.001]
  • [Cites] J Virol. 2008 Apr;82(7):3261-70 [18216099.001]
  • [Cites] PLoS One. 2008;3(3):e1781 [18335052.001]
  • [Cites] Curr HIV Res. 2008 Mar;6(2):108-16 [18336258.001]
  • [Cites] J Antimicrob Chemother. 2008 May;61(5):973-5 [18325896.001]
  • [Cites] Virus Res. 2008 Jun;134(1-2):64-73 [18308413.001]
  • [Cites] AIDS. 2008 Aug 20;22(13):1690-3 [18670237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10943-8 [18667707.001]
  • [Cites] Methods Mol Biol. 2009;485:87-105 [19020820.001]
  • [Cites] J Clin Microbiol. 1999 Dec;37(12):4099-106 [10565938.001]
  • [Cites] J Infect Dis. 2000 Mar;181(3):904-11 [10720511.001]
  • [Cites] J Virol. 2000 Jun;74(11):5357-62 [10799614.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1449-61 [11250910.001]
  • [Cites] J Virol. 2001 Jun;75(12):5604-13 [11356968.001]
  • [Cites] AIDS. 2001 May 25;15(8):1063-5 [11399992.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10090-5 [12119402.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1235-7 [12494923.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Jul;19(7):561-7 [12908933.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Aug;19(8):667-74 [13678469.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Aug;19(8):707-12 [14506784.001]
  • [Cites] J Med Virol. 2004 Jan;72(1):162-5 [14635026.001]
  • [Cites] J Clin Virol. 2004 Mar;29(3):152-9 [14962783.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 May;20(5):465-75 [15186520.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Nov;8(11):1887-95 [1489577.001]
  • [Cites] Lancet. 1993 May 8;341(8854):1171-4 [8098076.001]
  • [Cites] J Virol. 1999 Jan;73(1):152-60 [9847317.001]
  • (PMID = 19553318.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / RNA, Viral; 0 / Viral Proteins; 4B9XT59T7S / Zidovudine; EC 2.7.7.- / reverse transcriptase, Human immunodeficiency virus 1; EC 2.7.7.49 / HIV Reverse Transcriptase; EC 3.1.26.4 / Ribonuclease H; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ PMC2738196
  •  go-up   go-down


36. Nawar E, Mbulaiteye SM, Gallant JE, Wohl DA, Ardini M, Hendershot T, Goedert JJ, Rabkin CS, AIDS Cancer Cohort (ACC) Study Collaborators: Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS. Int J Cancer; 2005 Jun 10;115(2):296-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for Kaposi's sarcoma among HHV-8 seropositive homosexual men with AIDS.
  • Kaposi's sarcoma (KS) is a frequent complication of the acquired immunodeficiency syndrome (AIDS) in homosexual men.
  • Risk factors for developing this malignancy are uncertain, other than immunosuppression and coinfection with human herpesvirus 8 (HHV-8).
  • We therefore examined factors associated with KS in a cross-sectional analysis of 99 cases among 503 HHV-8 seropositive homosexual men with AIDS.
  • KS was less common in bisexual men compared to men who were exclusively homosexual (estimated RR = 0.6; 95% CI = 0.4-0.9) and inversely associated with number of female partners.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15688390.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CP / N01-CP-81017
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / K8.1 protein, Human herpesvirus 8; 0 / Viral Proteins
  •  go-up   go-down


37. Katano H, Sato Y, Hoshino S, Tachikawa N, Oka S, Morishita Y, Ishida T, Watanabe T, Rom WN, Mori S, Sata T, Weiden MD, Hoshino Y: Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient. Microbes Infect; 2007 Nov-Dec;9(14-15):1581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient.
  • High expression of STAT3 has also been implicated in cancer and lymphoma.
  • The lymphoma cells with anaplastic large cell morphology formed multiple nodular lesions in the lung of an acquired immunodeficiency syndrome (AIDS) patient with Kaposi's sarcoma.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • LANL HIV Databases. LANL HIV Databases .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 1999 Nov;11(6):490-6 [10550013.001]
  • [Cites] J Infect Dis. 2007 May 1;195(9):1303-10 [17396999.001]
  • [Cites] Virology. 2000 Apr 10;269(2):335-44 [10753712.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] J Exp Med. 2002 Feb 18;195(4):495-505 [11854362.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):791-5 [11857356.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):373-82 [12044013.001]
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Cell. 2002 Aug 23;110(4):521-9 [12202041.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] J Gen Virol. 2003 May;84(Pt 5):1123-31 [12692277.001]
  • [Cites] Science. 2003 Oct 17;302(5644):415-9 [14564000.001]
  • [Cites] J Immunol. 2004 May 15;172(10):6251-8 [15128813.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]
  • [Cites] Cell. 1988 Aug 12;54(4):497-504 [3401925.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2525-9 [2539592.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1157-64 [2323336.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7072-7 [9507017.001]
  • [Cites] Biochem J. 1998 Sep 1;334 ( Pt 2):297-314 [9716487.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):47-52 [10393835.001]
  • [Cites] J Med Virol. 1999 Aug;58(4):394-401 [10421407.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):939-47 [15705894.001]
  • [Cites] J Infect Dis. 2006 Mar 15;193(6):773-82 [16479510.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1301-7 [16697236.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • (PMID = 18024124.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000096; United States / NIDA NIH HHS / DA / R21 DA022162-02; United States / NCRR NIH HHS / RR / MO1 RR00096; United States / NIDA NIH HHS / DA / R21 DA022162-01; United States / NIDA NIH HHS / DA / DA022162; United States / NIDA NIH HHS / DA / DA022162-01; United States / NHLBI NIH HHS / HL / HL 59832; United States / NHLBI NIH HHS / HL / R01 HL059832; United States / NIDA NIH HHS / DA / DA022162-02; United States / NIDA NIH HHS / DA / R21 DA022162; United States / NHLBI NIH HHS / HL / HL57879; United States / NHLBI NIH HHS / HL / R01 HL057879
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / STAT3 Transcription Factor
  • [Other-IDs] NLM/ NIHMS36353; NLM/ PMC2200298
  •  go-up   go-down


38. Smith JS, Rosinska M, Trzcinska A, Pimenta JM, Litwinska B, Siennicka J: Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland. Sex Transm Infect; 2006 Apr;82(2):159-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine the type specific seroprevalence of herpes simplex virus (HSV) types 1 and 2 infections, stratified by age and gender, and associated risk factors for HSV-2 seropositivity in Poland.

  • MedlinePlus Health Information. consumer health - Genital Herpes.
  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Microbiol Infect Dis. 1999 Sep;18(9):678-80 [10534198.001]
  • [Cites] J Med Virol. 1999 Oct;59(2):194-7 [10459155.001]
  • [Cites] Schweiz Med Wochenschr. 2000 Feb 5;130(5):143-50 [10701231.001]
  • [Cites] J Med Virol. 2000 Jun;61(2):201-7 [10797375.001]
  • [Cites] Sex Transm Infect. 2000 Jun;76(3):183-7 [10961195.001]
  • [Cites] J Infect Dis. 2002 Oct 15;186 Suppl 1:S3-28 [12353183.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1652-61 [12444179.001]
  • [Cites] Sex Transm Dis. 2004 Apr;31(4):243-6 [15028940.001]
  • [Cites] Herpes. 2004 Apr;11 Suppl 1:36A-45A [15115628.001]
  • [Cites] Sex Transm Infect. 2004 Jun;80(3):185-91 [15170000.001]
  • [Cites] Clin Microbiol Infect. 2004 Jun;10(6):530-6 [15191381.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Jul;4(4):443-53 [15225092.001]
  • [Cites] Eur J Clin Microbiol. 1987 Jun;6(3):322 [3040393.001]
  • [Cites] Przegl Epidemiol. 1987;41(3):286-94 [2829284.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):54-6 [2837392.001]
  • [Cites] Przegl Epidemiol. 1991;45(4):262-6 [1668700.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):358-63 [8314322.001]
  • [Cites] Int J STD AIDS. 1994 Mar-Apr;5(2):113-6 [8031912.001]
  • [Cites] Ann Intern Med. 1994 Dec 1;121(11):847-54 [7978697.001]
  • [Cites] N Engl J Med. 1995 Sep 21;333(12):770-5 [7643884.001]
  • [Cites] Scand J Infect Dis. 1995;27(3):195-9 [8539540.001]
  • [Cites] J Clin Invest. 1997 Mar 1;99(5):1092-7 [9062368.001]
  • [Cites] Int J Epidemiol. 1997 Aug;26(4):698-709 [9279600.001]
  • [Cites] N Engl J Med. 1997 Oct 16;337(16):1105-11 [9329932.001]
  • [Cites] Clin Infect Dis. 1998 Mar;26(3):541-53; quiz 554-5 [9524821.001]
  • [Cites] APMIS. 1998 Mar;106(3):417-24 [9548432.001]
  • [Cites] Sex Transm Infect. 1998 Jun;74(3):216-8 [9849560.001]
  • [Cites] Clin Microbiol Rev. 1999 Jan;12(1):1-8 [9880471.001]
  • [Cites] Sex Transm Dis. 1999 Feb;26(2):67-74 [10029978.001]
  • [Cites] Tidsskr Nor Laegeforen. 1999 Jun 20;119(16):2323-6 [10414195.001]
  • [Cites] Sex Transm Infect. 1999 Jun;75(3):168-71 [10448394.001]
  • [Cites] N Engl J Med. 1999 Nov 4;341(19):1432-8 [10547406.001]
  • (PMID = 16581747.001).
  • [ISSN] 1368-4973
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2564693
  •  go-up   go-down


39. Minang JT, Trivett MT, Coren LV, Barsov EV, Piatak M Jr, Ott DE, Ohlen C: Nef-mediated MHC class I down-regulation unmasks clonal differences in virus suppression by SIV-specific CD8(+) T cells independent of IFN-gamma and CD107a responses. Virology; 2009 Aug 15;391(1):130-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CTL antiviral activity is dependent on recognition of antigenic peptides associated with MHC class I molecules on infected target cells, and CTL activation can be impaired by Nef-mediated down-regulation of MHC class I molecules.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Jun 1;109(11):4832-8 [17303696.001]
  • [Cites] J Virol. 2007 Nov;81(21):11703-12 [17699580.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):63-75 [10880527.001]
  • [Cites] J Virol. 2000 Aug;74(16):7485-95 [10906202.001]
  • [Cites] Nature. 2000 Sep 21;407(6802):386-90 [11014195.001]
  • [Cites] J Virol. 2000 Nov;74(22):10581-8 [11044102.001]
  • [Cites] J Virol. 2001 Jan;75(2):799-808 [11134293.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):334-8 [11460164.001]
  • [Cites] J Virol. 2001 Nov;75(21):10187-99 [11581387.001]
  • [Cites] Immunol Lett. 2001 Nov 1;79(1-2):15-20 [11595285.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):1107-16 [18178851.001]
  • [Cites] J Virol. 2008 Mar;82(6):3139-46 [18199657.001]
  • [Cites] J Virol. 2000 Feb;74(3):1149-57 [10627525.001]
  • [Cites] J Virol. 2000 Jun;74(12):5691-701 [10823877.001]
  • [Cites] Virology. 2008 Mar 15;372(2):430-41 [18068748.001]
  • [Cites] Science. 2008 May 9;320(5877):760-4 [18467582.001]
  • [Cites] Nature. 2002 Jan 17;415(6869):335-9 [11797012.001]
  • [Cites] J Virol. 2002 Feb;76(4):1626-31 [11799157.001]
  • [Cites] Annu Rev Med. 2002;53:499-518 [11818487.001]
  • [Cites] J Immunol. 2002 Apr 1;168(7):3660-6 [11907132.001]
  • [Cites] Vaccine. 2002 May 6;20(15):2011-5 [11983265.001]
  • [Cites] J Virol. 2002 Aug;76(15):7535-43 [12097566.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3400-6 [12218162.001]
  • [Cites] J Virol. 2002 Oct;76(20):10507-11 [12239328.001]
  • [Cites] J Virol. 2002 Dec;76(23):12360-4 [12414978.001]
  • [Cites] J Virol. 2003 Mar;77(5):3077-83 [12584333.001]
  • [Cites] J Virol. 2003 Apr;77(7):4169-80 [12634375.001]
  • [Cites] J Virol. 2003 Aug;77(16):9029-40 [12885919.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3718-24 [14500671.001]
  • [Cites] J Immunol Methods. 2003 Oct 1;281(1-2):65-78 [14580882.001]
  • [Cites] Nat Med. 2004 Mar;10(3):282-9 [14770175.001]
  • [Cites] J Virol. 2004 Jul;78(13):7069-78 [15194783.001]
  • [Cites] J Virol. 2004 Oct;78(19):10588-97 [15367626.001]
  • [Cites] J Immunol Methods. 1990 Apr 17;128(2):189-201 [1691237.001]
  • [Cites] Science. 1990 Jun 1;248(4959):1109-12 [2160735.001]
  • [Cites] Biotechniques. 1990 May;8(5):528-35 [2357375.001]
  • [Cites] AIDS Res Hum Retroviruses. 1990 Nov;6(11):1221-31 [2078405.001]
  • [Cites] Cell. 1991 May 17;65(4):651-62 [2032289.001]
  • [Cites] J Gen Virol. 1994 Mar;75 ( Pt 3):529-43 [8126450.001]
  • [Cites] J Virol. 1994 May;68(5):2906-14 [8151761.001]
  • [Cites] J Virol. 1994 Sep;68(9):6103-10 [8057491.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):228-32 [7808489.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S83-8 [7865339.001]
  • [Cites] Nat Med. 1996 Mar;2(3):338-42 [8612235.001]
  • [Cites] J Exp Med. 1997 Jul 7;186(1):7-16 [9206992.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):397-401 [9450757.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1113-22 [9529327.001]
  • [Cites] J Virol. 1998 May;72(5):3646-57 [9557645.001]
  • [Cites] J Gen Virol. 1998 Nov;79 ( Pt 11):2717-27 [9820147.001]
  • [Cites] J Virol. 1999 Mar;73(3):1964-73 [9971776.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5127-33 [10227983.001]
  • [Cites] Annu Rev Immunol. 1999;17:739-79 [10358773.001]
  • [Cites] Immunity. 1999 Jun;10(6):661-71 [10403641.001]
  • [Cites] J Virol. 2004 Dec;78(23):13335-44 [15542684.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):36-40 [15611225.001]
  • [Cites] J Virol. 2005 Aug;79(16):10547-60 [16051847.001]
  • [Cites] J Med Primatol. 2005 Oct;34(5-6):303-12 [16128925.001]
  • [Cites] J Virol. 2006 May;80(9):4469-81 [16611907.001]
  • [Cites] Blood. 2006 Jul 1;108(1):209-17 [16522814.001]
  • [Cites] Nature. 2006 Sep 21;443(7109):350-4 [16921384.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1198-202 [16917489.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3414-9 [16882705.001]
  • [Cites] J Exp Med. 2006 Nov 27;203(12):2661-72 [17116733.001]
  • [Cites] J Virol. 2007 Feb;81(3):1517-23 [17135324.001]
  • [Cites] Genes Funct. 1997 Dec;1(5-6):321-35 [17366702.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 Mar;23(3):456-65 [17411379.001]
  • (PMID = 19555986.001).
  • [ISSN] 1096-0341
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / PHS HHS / / HHSN261200800001E; United States / NCI NIH HHS / CA / N01CO12400; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CA / HHSN261200800001E
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, nef; 0 / Histocompatibility Antigens Class I; 0 / Lysosomal-Associated Membrane Protein 1; 0 / RNA, Viral; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS122691; NLM/ PMC2716421
  •  go-up   go-down


40. Petrovsky N: Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine; 2006 Apr 12;24 Suppl 2:S2-26-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the enormous number of candidates, potency has invariably been associated with increased toxicity, and this more than anything else has precluded their use, particularly in prophylactic vaccines where safety issues are paramount.
  • Thus, adjuvants based on inulin have enormous potential for use in vaccines against both pathogens and cancer.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Immunol. 1991 Mar;28(3):279-84 [1850114.001]
  • [Cites] Can J Comp Med. 1985 Apr;49(2):149-51 [4016580.001]
  • [Cites] Infect Immun. 1986 Mar;51(3):816-25 [3949381.001]
  • [Cites] Vaccine. 1991 May;9(5):351-7 [1872020.001]
  • [Cites] Vaccine. 1991 Jun;9(6):408-15 [1887671.001]
  • [Cites] Immunol Today. 1992 Jan;13(1):11-6 [1739426.001]
  • [Cites] Biotechnology. 1992;20:431-49 [1600387.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Aug;8(8):1409-11 [1466969.001]
  • [Cites] Vaccine. 1993;11(3):293-306 [8447157.001]
  • [Cites] Immunol Today. 1993 Feb;14(2):95-6 [8095391.001]
  • [Cites] Immunol Today. 1993 Jun;14(6):281-4 [8104409.001]
  • [Cites] Vaccine. 1993;11(9):914-8 [8212836.001]
  • [Cites] Pharm Biotechnol. 1995;6:525-41 [7551234.001]
  • [Cites] Pharm Biotechnol. 1995;6:559-80 [7551236.001]
  • [Cites] Vaccine. 1995 Oct;13(14):1375-82 [8585296.001]
  • [Cites] Dev Biol Stand. 1998;92:241-8 [9554280.001]
  • [Cites] Kidney Int. 1999 May;55(5):1878-84 [10231450.001]
  • [Cites] Bibl Tuberc. 1956;(10):130-48 [13341884.001]
  • [Cites] Mol Biotechnol. 2002 Jun;21(2):129-48 [12059113.001]
  • [Cites] Br Med J. 1969 Mar 15;1(5645):663-6 [5774314.001]
  • [Cites] Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317-25 [4606813.001]
  • [Cites] Rev Infect Dis. 1980 May-Jun;2(3):370-83 [6997966.001]
  • [Cites] J Immunol. 1991 Jan 15;146(2):431-7 [1987271.001]
  • (PMID = 16823913.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI061142; United States / NIAID NIH HHS / AI / U01 AI061142-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 9005-80-5 / Inulin
  • [Number-of-references] 28
  • [Other-IDs] NLM/ NIHMS295863; NLM/ PMC3101117
  •  go-up   go-down


41. Al-Harthi L, Voris J, Du W, Wright D, Nowicki M, Frederick T, Landay A, Kovacs A: Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis; 2006 May 01;193(9):1202-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV/HCV coinfection is associated with an increased number of CD4+ and CD8+ primed/memory T cells.
  • CONCLUSIONS: HCV does not affect immune responses to HAART in HIV/HCV-coinfected individuals but is associated with an expansion of CD4+ and CD8+ memory T cell subsets.

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2003 Jun 15;187(12):1951-8 [12792872.001]
  • [Cites] AIDS. 2002 Jul 5;16(10):1423-5 [12131221.001]
  • [Cites] J Virol. 1999 Aug;73(8):6506-16 [10400746.001]
  • [Cites] AIDS. 2002 Sep 27;16(14):1915-23 [12351951.001]
  • [Cites] J Hepatol. 1997 Jan;26(1):1-5 [9147999.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1711-9 [11748273.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):65-73 [12925958.001]
  • [Cites] JAMA. 2002 Jul 10;288(2):199-206 [12095384.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):492-7 [11170959.001]
  • [Cites] J Clin Microbiol. 1997 Dec;35(12):3274-7 [9399533.001]
  • [Cites] Lancet. 2000 Nov 25;356(9244):1800-5 [11117912.001]
  • [Cites] World J Gastroenterol. 2000 Dec;6(6):805-811 [11819700.001]
  • [Cites] Infect Dis Clin North Am. 2000 Sep;14(3):741-59 [10987118.001]
  • [Cites] Blood. 2004 May 15;103(10):3854-9 [14739225.001]
  • [Cites] Nat Rev Immunol. 2005 Feb;5(2):101-11 [15662368.001]
  • [Cites] J Infect Dis. 1997 Jan;175(1):164-8 [8985212.001]
  • [Cites] J Infect Dis. 1999 May;179(5):1254-8 [10191232.001]
  • [Cites] J Clin Immunol. 2005 Mar;25(2):134-41 [15821890.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Nov;22(11):675-80 [14574616.001]
  • [Cites] Przegl Epidemiol. 2003;57(2):317-20 [12910600.001]
  • [Cites] Clin Infect Dis. 2001 May 15;32(10):1487-93 [11317251.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):106-11 [11242051.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):95-100 [12520703.001]
  • [Cites] AIDS. 1998 Mar 5;12(4):381-8 [9520167.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):167-70 [9665297.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12232-41 [14709551.001]
  • [Cites] J Virol. 2004 Jun;78(11):5535-45 [15140950.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6675-83 [15153483.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30 Suppl 1:S77-84 [10770916.001]
  • [Cites] J Infect Dis. 1995 Dec;172(6):1503-8 [7594709.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3760-3 [11574612.001]
  • [Cites] Virology. 1998 May 10;244(2):504-12 [9601518.001]
  • [Cites] Arch Intern Med. 2002 Oct 14;162(18):2125-32 [12374521.001]
  • [Cites] Immunology. 2005 Mar;114(3):322-35 [15720434.001]
  • [Cites] Epidemiology. 1998 Mar;9(2):117-25 [9504278.001]
  • [Cites] Nat Immunol. 2003 Mar;4(3):225-34 [12563257.001]
  • (PMID = 16586355.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000079; United States / NIAID NIH HHS / AI / U01-AI-42590; United States / NIAID NIH HHS / AI / U01 AI031834; United States / NIAID NIH HHS / AI / R56 AI052065; United States / NIAID NIH HHS / AI / U01 AI035004; United States / NICHD NIH HHS / HD / U01-HD-32632; United States / NIAID NIH HHS / AI / U01 AI034989; United States / NIAID NIH HHS / AI / R01 AI052065; United States / NCRR NIH HHS / RR / M01-RR-00083; United States / NIAID NIH HHS / AI / R01 AI052065-01; United States / NCRR NIH HHS / RR / M01 RR000071; United States / NIAID NIH HHS / AI / U01-AI-34994; United States / NIAID NIH HHS / AI / U01-AI-35004; United States / NIAID NIH HHS / AI / U01-AI-31834; United States / NCRR NIH HHS / RR / M01-RR-00079; United States / NIAID NIH HHS / AI / U01 AI034994; United States / NICHD NIH HHS / HD / U01-HD-3-2632-11; United States / NIAID NIH HHS / AI / U01-AI-34993; United States / NCRR NIH HHS / RR / M01-RR-00071; United States / NIAID NIH HHS / AI / U01 AI034993; United States / NCRR NIH HHS / RR / M01 RR000083; United States / NIAID NIH HHS / AI / U01-AI-34989; United States / NICHD NIH HHS / HD / U01 HD032632; United States / NIAID NIH HHS / AI / U01 AI042590; United States / PHS HHS / / R01 052065
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antigens, CD; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS300010; NLM/ PMC3126663
  •  go-up   go-down


42. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, Estes JD, Thacker TC, Crandall KA, McArthur JC, Burton GF: Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol; 2008 Jun;82(11):5548-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Throughout the natural course of human immunodeficiency virus (HIV) infection, follicular dendritic cells (FDCs) trap and retain large quantities of particle-associated HIV RNA in the follicles of secondary lymphoid tissue.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • LANL HIV Databases. LANL HIV Databases .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Evol. 1995 Mar;40(3):249-59 [7723052.001]
  • [Cites] Nature. 1995 Mar 9;374(6518):124-6 [7877682.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;201:141-59 [7587348.001]
  • [Cites] Nature. 1995 Oct 26;377(6551):740-4 [7477265.001]
  • [Cites] Science. 1996 Nov 8;274(5289):985-9 [8875941.001]
  • [Cites] Annu Rev Immunol. 1997;15:649-74 [9143703.001]
  • [Cites] Nature. 1997 May 8;387(6629):183-8 [9144289.001]
  • [Cites] Nature. 1997 May 8;387(6629):188-91 [9144290.001]
  • [Cites] Immunol Rev. 1997 Apr;156:39-52 [9176698.001]
  • [Cites] Immunol Rev. 1997 Apr;156:185-97 [9176708.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):1173-6 [9327753.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1291-5 [9360926.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1295-300 [9360927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7 [9371822.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Nat Med. 1998 Mar;4(3):341-5 [9500610.001]
  • [Cites] Bioinformatics. 1998;14(9):817-8 [9918953.001]
  • [Cites] Nat Med. 1999 May;5(5):512-7 [10229227.001]
  • [Cites] Annu Rev Immunol. 1999;17:625-56 [10358770.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10958-61 [10500107.001]
  • [Cites] Syst Biol. 2004 Oct;53(5):793-808 [15545256.001]
  • [Cites] J Gen Virol. 2005 Dec;86(Pt 12):3369-73 [16298984.001]
  • [Cites] J Theor Biol. 2006 Jan 7;238(1):220-9 [16005903.001]
  • [Cites] Bioinformatics. 2006 Mar 15;22(6):768-70 [16410317.001]
  • [Cites] J Mol Evol. 1981;17(6):368-76 [7288891.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):217-24 [3180126.001]
  • [Cites] Annu Rev Immunol. 2000;18:665-708 [10837072.001]
  • [Cites] J Neurovirol. 2000 May;6 Suppl 1:S70-81 [10871768.001]
  • [Cites] AIDS. 1999;13 Suppl A:S49-58 [10885762.001]
  • [Cites] J Virol. 2000 Sep;74(17):7997-8002 [10933708.001]
  • [Cites] Genetics. 2000 Oct;156(2):879-91 [11014833.001]
  • [Cites] Mol Ecol. 2000 Oct;9(10):1657-9 [11050560.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):690-6 [11123354.001]
  • [Cites] J Virol. 2001 Mar;75(6):2597-603 [11222682.001]
  • [Cites] Annu Rev Med. 2002;53:557-93 [11818490.001]
  • [Cites] J Mol Evol. 2002 Mar;54(3):396-402 [11847565.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2408-14 [11859132.001]
  • [Cites] Syst Biol. 2002 Oct;51(5):673-88 [12396583.001]
  • [Cites] HIV Clin Trials. 2003 Mar-Apr;4(2):137-43 [12671782.001]
  • [Cites] J Virol. 2003 May;77(9):5540-6 [12692259.001]
  • [Cites] AIDS Rev. 2003 Jan-Mar;5(1):3-18 [12875103.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1572-4 [12912839.001]
  • [Cites] Curr Opin Microbiol. 2003 Aug;6(4):410-6 [12941414.001]
  • [Cites] Trends Biotechnol. 2003 Oct;21(10):420-3 [14512225.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] J Leukoc Biol. 2003 Nov;74(5):631-4 [12960251.001]
  • [Cites] Exp Mol Pathol. 1968 Feb;8(1):75-89 [4170142.001]
  • [Cites] Immunology. 1979 May;37(1):69-76 [468304.001]
  • [Cites] Immunol Rev. 1980;53:29-59 [6162778.001]
  • [Cites] Immunol Rev. 1980;53:3-28 [7009406.001]
  • [Cites] Annu Rev Immunol. 1989;7:91-109 [2653380.001]
  • [Cites] APMIS Suppl. 1989;8:16-23 [2660879.001]
  • [Cites] AIDS Res Hum Retroviruses. 1990 Aug;6(8):967-71 [2223243.001]
  • [Cites] Trends Genet. 1991 Mar;7(3):71-4 [2031285.001]
  • [Cites] J Infect Dis. 1991 Dec;164(6):1051-7 [1955708.001]
  • [Cites] J Pathol. 1993 Jun;170(2):115-20 [7688416.001]
  • [Cites] Ann N Y Acad Sci. 1993 Oct 29;693:52-64 [8267295.001]
  • [Cites] Eur J Immunol. 1995 Aug;25(8):2362-9 [7664798.001]
  • (PMID = 18385252.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI57007; United States / NIAID NIH HHS / AI / R01 AI057007; United States / NIAID NIH HHS / AI / R21 AI039963; United States / NIAID NIH HHS / AI / R56 AI039963; United States / NIAID NIH HHS / AI / AI39963; United States / NIAID NIH HHS / AI / R01 AI039963; United States / NIGMS NIH HHS / GM / GM66276; United States / NIGMS NIH HHS / GM / R01 GM066276
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2395176
  •  go-up   go-down


43. Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, Zheng ZM: Could human papillomaviruses be spread through blood? J Clin Microbiol; 2005 Nov;43(11):5428-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HPV infection through abrasion of the skin or sexual intercourse causes benign warts and sometimes cancer.
  • HPV DNA detected in the blood has been interpreted as having originated from metastasized cancer cells.
  • Among the eight patients, seven acquired HIV from transfusion (three associated with hemophilia) and one acquired HIV through vertical transmission; this patient also had received a transfusion before sampling.

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] Hum Immunol. 2003 May;64(5):538-42 [12691704.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):14-9 [12807940.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):52-6 [12807946.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7215-20 [14612516.001]
  • [Cites] J Infect Dis. 2004 Jul 1;190(1):37-45 [15195241.001]
  • [Cites] Am J Clin Pathol. 1991 Apr;95(4):540-6 [1849701.001]
  • [Cites] J Virol. 2004 Nov;78(21):11451-60 [15479788.001]
  • [Cites] J Virol. 1992 Apr;66(4):2057-66 [1312620.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(6):522-6 [1335412.001]
  • [Cites] J Virol. 1993 Nov;67(11):6413-23 [8411343.001]
  • [Cites] J Infect Dis. 1994 Nov;170(5):1077-85 [7963696.001]
  • [Cites] Gut. 1995 Jul;37(1):87-90 [7672688.001]
  • [Cites] Fertil Steril. 1996 May;65(5):1026-30 [8612829.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1008-12 [9060540.001]
  • [Cites] Fertil Steril. 1997 Jun;67(6):1152-5 [9176459.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):796-802 [9182978.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1343-9 [9358128.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] J Gen Virol. 1998 Sep;79 ( Pt 9):2127-35 [9747721.001]
  • [Cites] J Gen Virol. 1999 Apr;80 ( Pt 4):1035-43 [10211974.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1391-6 [10334523.001]
  • [Cites] J Gen Virol. 1999 Jul;80 ( Pt 7):1725-33 [10423141.001]
  • [Cites] J Med Virol. 2005 Mar;75(3):435-9 [15648077.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):695-700 [15721413.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2862-7 [15837733.001]
  • [Cites] J Clin Virol. 2004 Dec;31(4):292-7 [15494272.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6132-6 [10626803.001]
  • [Cites] JAMA. 2000 Feb 23;283(8):1031-7 [10697063.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):33-6 [11029768.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4171-5 [11106228.001]
  • [Cites] Oral Oncol. 2001 Feb;37(2):146-52 [11167141.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2799-803 [11306446.001]
  • [Cites] J Clin Virol. 2001 May;21(2):129-34 [11378493.001]
  • [Cites] J Infect Dis. 2001 Sep 15;184(6):682-90 [11517428.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):269-72 [11531278.001]
  • [Cites] Pathologica. 2001 Oct;93(5):531-4 [11725354.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):3-6 [11815394.001]
  • [Cites] Oral Oncol. 2002 Sep;38(6):591-6 [12167437.001]
  • [Cites] J Med Virol. 2002 Nov;68(3):412-6 [12226830.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):721-8 [12354793.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3187-92 [12374687.001]
  • [Cites] Prostate. 2002 Dec 1;53(4):263-76 [12430138.001]
  • [Cites] Transpl Int. 2003 Mar;16(3):146-53 [12664208.001]
  • (PMID = 16272465.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / SC / Z01 SC010357-06; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC1287818
  •  go-up   go-down


44. Moursi AM, Fernandez JB, Daronch M, Zee L, Jones CL: Nutrition and oral health considerations in children with special health care needs: implications for oral health care providers. Pediatr Dent; 2010 Jul-Aug;32(4):333-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this article was to discuss: nutritional and oral health factors routinely observed in most chronic childhood disorders; dietary modifications associated with select systemic disorders and how they may impact oral health in children; and the following factors common to chronic disorders associated with diet modifications-decreased appetite and increased nutritional risk; frequency of food intake; parental overindulgence; long-term use of cariogenic medications; and xerostomia.
  • Characteristics of childhood disorders that require dietary modifications (congenital heart disease, cystic fibrosis, cancer, AIDS/HIV, diabetes mellitus, and phenylketonuria) are summarized.


45. Olivieri KC, Agopian KA, Mukerji J, Gabuzda D: Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retroviruses; 2010 Apr;26(4):495-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human immunodeficiency virus type 1 (HIV) infection of the central nervous system frequently causes HIV-associated neurocognitive disorders (HAND).
  • To determine whether HIV nef undergoes adaptive selection in brain, we cloned 100 nef sequences (n = 30 brain and n = 70 lymphoid) from four patients with AIDS and HIV-associated dementia (HAD).

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • LANL HIV Databases. LANL HIV Databases .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6437-46 [11086083.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Jun;25(6):583-601 [19500015.001]
  • [Cites] J Virol. 2002 Jun;76(12):6277-92 [12021361.001]
  • [Cites] J Virol. 2003 Nov;77(22):12336-45 [14581570.001]
  • [Cites] J Exp Med. 2002 Sep 2;196(5):589-604 [12208875.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Biochemistry. 1998 Oct 20;37(42):14683-91 [9778343.001]
  • [Cites] J Virol. 1999 Feb;73(2):897-906 [9882290.001]
  • [Cites] Virology. 2004 Nov 24;329(2):302-18 [15518810.001]
  • [Cites] FASEB J. 2004 Dec;18(15):1851-61 [15576488.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):69-81 [15630430.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2712-9 [15728479.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1208-22 [15703242.001]
  • [Cites] J Virol. 2006 Jan;80(1):62-72 [16352531.001]
  • [Cites] J Virol. 2006 Mar;80(6):3050-61 [16501114.001]
  • [Cites] Brain. 2006 Jul;129(Pt 7):1872-83 [16735456.001]
  • [Cites] Virology. 2007 Feb 5;358(1):119-35 [16979207.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] J Mol Biol. 2007 Nov 16;374(1):121-9 [17920628.001]
  • [Cites] Stat Med. 2008 Oct 15;27(23):4779-89 [18381707.001]
  • [Cites] J Virol. 2008 Nov;82(21):10418-28 [18715919.001]
  • [Cites] Glia. 2001 Nov;36(2):165-79 [11596125.001]
  • (PMID = 20377428.001).
  • [ISSN] 1931-8405
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ DQ358015/ DQ358016/ DQ358017/ DQ358018/ DQ358019/ DQ358020/ DQ358021/ DQ358022/ DQ358023/ DQ358024/ DQ358025/ DQ358026/ DQ358027/ DQ358028/ DQ358029/ DQ358030/ DQ358031/ DQ358032/ DQ358033/ DQ358034/ DQ358035/ DQ358036/ DQ358037/ DQ358038/ DQ358039/ DQ358040/ DQ358041/ DQ358042/ DQ358043/ DQ358044/ DQ358045/ DQ358046/ DQ358047/ DQ885391/ DQ885392/ DQ885393/ DQ885394/ DQ885395/ DQ885396/ DQ885397/ DQ885398/ DQ885399/ DQ885400/ DQ885401/ DQ885402/ DQ885403/ DQ885404/ DQ885405/ DQ885406/ DQ885407/ DQ885408/ DQ885409/ DQ885410/ DQ885411/ DQ885412/ DQ885413/ DQ885414/ DQ885415/ DQ885416/ DQ885417/ DQ885418/ DQ885419/ DQ885420/ DQ885421/ DQ885422/ DQ885423/ DQ885424/ DQ885425/ DQ885426/ DQ885427/ DQ885428/ DQ885429/ DQ885430/ DQ885431/ DQ885432/ DQ885433/ DQ885434/ DQ885435/ DQ885436/ DQ885437/ DQ885438/ DQ885439/ DQ885440/ DQ885441/ DQ885442/ DQ885443/ DQ885444/ DQ885445/ DQ885446/ DQ885447/ DQ885448/ DQ885449/ DQ885450/ DQ885451/ DQ885452/ DQ885453/ DQ885454/ GU049621/ GU049622/ GU049623/ GU049624/ GU049625/ GU049626/ GU049627/ GU049628/ GU049629/ GU049630/ GU049631/ GU049632/ GU049633/ GU049634/ GU049635/ GU049636/ GU049637/ GU049638/ GU049639/ GU049640/ GU049641/ GU049642/ GU049643/ GU049644/ GU049645/ GU049646/ GU049647/ GU049648/ GU049649/ GU049650/ GU049651/ GU049652/ GU049653/ GU049654/ GU049655/ GU049656/ GU049657/ GU049658/ GU049659
  • [Grant] United States / NIA NIH HHS / AG / T32 AG00222; United States / NIAID NIH HHS / AI / AI073415-02; United States / NIMH NIH HHS / MH / MH083588-10A2; United States / NIMH NIH HHS / MH / R01 MH083588; United States / NIMH NIH HHS / MH / MH083588-11; United States / NIMH NIH HHS / MH / MH83588; United States / NIMH NIH HHS / MH / MH083588-12; United States / NIAID NIH HHS / AI / AI073415-01A2; United States / NIMH NIH HHS / MH / R01 MH083588-10A2; United States / NIAID NIH HHS / AI / R21 AI073415-01A2; United States / NIMH NIH HHS / MH / R01 MH083588-11; United States / NIAID NIH HHS / AI / R21 AI073415-02; United States / NIMH NIH HHS / MH / R01 MH083588-12; United States / NIAID NIH HHS / AI / T32 AI007386; United States / NIAID NIH HHS / AI / AI73415; United States / NIAID NIH HHS / AI / R21 AI073415
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / nef Gene Products, Human Immunodeficiency Virus; 0 / nef protein, Human immunodeficiency virus 1
  • [Other-IDs] NLM/ PMC2933169
  •